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ABSTRACT 
Cardiovascular disease (CVD) remains the most common cause of death globally. Dyslipidaemia 
is one of the most important risk factors that leads to CVD. It can be due to a monogenic condition or 
to polygenic/environmental causes as diabetes, obesity, tobacco use, excess of alcohol or reduced 
physical activity. The identification of the individuals at risk and the distinction of these two types of 
dyslipidaemia is important for a correct cardiovascular risk assessment, counselling, and treatment 
reducing, this way, cardiovascular mortality. 
Familial hypercholesterolaemia (FH) is an autosomal dominant disorder of cholesterol 
metabolism. Most commonly, FH results from inherited defects in the Low-Density Lipoprotein 
Receptor Gene (LDLR) leading to increased levels of circulating LDL cholesterol and lipid accumulation 
in arteries and tendons. Mutations in other genes as the apolipoprotein B gene (APOB) and proprotein 
convertase subtilisin/kexin type 9 gene (PCSK9), are also responsible for FH. The distribution pattern 
of apolipoprotein E gene (APOE) polymorphisms affects the affinity to lipoprotein receptors and, 
consequently, the clearance of dietary fat from the blood, also causing dyslipidaemia.  
The homozygous form of FH is rare and more severe, but the heterozygous form is common, with 
a frequency of 1/500 in most of European countries, although underdiagnosed in several populations, 
including the portuguese. 
FH is characterized by increased levels of plasmatic cholesterol since birth, which results in 
cholesterol deposits in extravascular tissues that can be identified in young patients (below 45 years 
old): xanthelasma, corneal arcus deposits and tendon xanthomas. This accumulation can cause 
premature arteriosclerosis and coronary heart disease (CHD). The presence of tendon xanthomas allows 
the differentiation of FH from other causes of hypercholesterolaemia as polygenic 
hypercholesterolaemia.  
More than 1700 different alterations in LDLR gene have been described worldwide. However, the 
functional studies for the great majority of these variants, have not been performed. For patients carrying 
these variants, a definitive molecular diagnosis for FH is not possible, representing a serious problem 
for FH diagnosis. 
In 1999, the Portuguese FH study was established at the National Institute of Health to 
identify the genetic cause of hypercholesterolaemia in individuals with a clinical diagnosis of FH. Index 
patients are included in this study using an adaptation of the Simon Broome (SB) criteria. Nonetheless, 
FH remains underdiagnosed and undertreated in the portuguese population. 
The main aim of this project was to perform the molecular identification of genetic variants in 
LDLR, APOB and APOE genes, causing dyslipidaemia in patients referred to the Portuguese FH Study 
in 2015/2016 with a clinical diagnosis of FH, in order to improve the identification of individuals at risk. 
Functional studies in RNA for putative splicing variants were also performed. 
The molecular diagnosis was performed for 60 index cases. Genomic DNA was isolated from 
peripheral blood lymphocytes using the salting out method. The 18 exons and promotor region of LDLR, 
part of exons 26 and 29 of APOB and exon 4 of APOE were amplified by PCR and sequenced by direct 
Sanger sequencing.  
A total of 18 variants were identified in 24 of these patients. The cascade screening in relatives of 
these 24 index patients allowed the identification and genetic characterization of additional 19 FH 
patients in Portugal. All alterations found have been previously reported, although only 11 had been 
functionally assessed. The search for large rearrangements was performed by Multiplex Ligation-
dependent Probe Amplification (MLPA). In silico analysis was performed for all the variants found. 
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In order to access the effect of splicing mutations, RNA was isolated from patients’ blood with 
RNeasy® Mini Kit (Qiagen), after isolation of peripheral blood mononuclear cells, and then transcribed 
to cDNA. Regions of interest were amplified with specific primers designed to evaluate the effect on 
cDNA of two of the tree putative splicing variants found in LDLR gene. Specific detection of each 
transcript was accessed by an agarose gel and the fragments were sequenced by Sanger sequencing. 
Both alterations lead to skipping of an entire exon and create premature stop codons: c.1060+1G>A 
causes an inactivation of the donor site in intron 7 resulting in skipping of exon 7; the alteration in the 
last nucleotide of exon 16 (c.2389G>A) creates a new acceptor site causing the skipping of exon 16. 
The early genetic identification of a mutation, confirming the clinical diagnosis of FH, is very 
important, especially for young patients, since they can receive appropriate dietary and lifestyle advice 
and adequate therapeutic measures providing them longer and better lives.    
 
Keywords: Familial Hypercholesterolaemia, LDLR, molecular diagnosis, splicing mutations 
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RESUMO 
As doenças cardiovasculares (DCV) afetam o funcionamento normal do coração e dos vasos 
sanguíneos. Existem vários tipos de doenças cardiovasculares, sendo as principais a doença das artérias 
coronárias e a doença das artérias do cérebro. A doença coronária é, maioritariamente, provocada por 
aterosclerose, uma doença progressiva e inflamatória que resulta na formação de placas ateroscleróticas. 
Agentes infeciosos ou concentrações elevadas de lipoproteínas de baixa densidade (LDL) no sangue 
podem levar ao aparecimento destas placas na parede interna das artérias impedindo a circulação 
sanguínea.  
As doenças cardiovasculares são uma das causas de morte mais comum no planeta. Fatores de risco 
como o uso de tabaco, obesidade, prática de exercício físico reduzida, consumo excessivo de álcool, 
diabetes, hipertensão, stress e dislipidémia aumentam a probabilidade de ocorrência prematura deste 
tipo de doenças. 
A dislipidémia é um dos mais importantes fatores de risco da aterosclerose, uma vez que se 
caracteriza por anomalias quantitativas ou qualitativas dos lípidos no sangue. A identificação de 
indivíduos em risco e o conhecimento da causa de hipercolesterolemia é de extrema importância para 
que estes indivíduos possam ser corretamente tratados evitando-se, assim, a morte devida a esta causa. 
A Hipercolesterolemia Familiar (FH) é uma doença autossómica dominante do metabolismo do 
colesterol. A FH é hereditária e resulta, maioritariamente, de mutações no gene do recetor das 
lipoproteínas de baixa densidade (LDLR) cuja função é a remoção do colesterol LDL do plasma, 
transportando-o para o fígado, onde é processado. Ficando esta função afetada, os níveis de colesterol 
LDL circulante, aumentam. Mutações noutros genes como o gene da apolipoproteína B-100 (APOB) e 
da pro-proteína convertase subtilisina/quexina tipo 9 (PCSK9) são também causa, embora menos 
frequente, desta doença. Alterações no gene da apolipoproteína E (APOE) afetam a afinidade com os 
recetores de lipoproteínas e, consequentemente, a remoção do colesterol do sangue, podendo também 
causar dislipidémia.  
A forma homozigótica da FH é rara e mais severa, mas a heterozigótica é comum embora sub-
diagnosticada em muitas populações, nomeadamente na portuguesa. Estima-se que, na maioria dos 
países europeus, a prevalência destas duas formas seja 1/1000000 e 1/500 indivíduos, respetivamente. 
O colesterol total, na forma heterozigótica, varia entre 290 e 500 mg/dL (com LDL>190 mg/dl) e na 
forma homozigótica, habitualmente, encontra-se entre os 600 mg/dL e os 1000 mg/dL.  
O nível elevado de colesterol no plasma resulta, frequentemente, na formação de depósitos de 
colesterol nos tecidos extravasculares que, por vezes, podem ser facilmente identificados em indivíduos 
ainda jovens (abaixo dos 45 anos): xantelasmas, arco corneano e, mais difíceis de reconhecer mas mais 
específicos, os xantomas nos tendões. A presença de valores altos de colesterol LDL desde o nascimento, 
característico desta doença, leva a um incremento do risco de doença coronária prematura. Este fenótipo 
permite diferenciar a FH de outras causas de hipercolesterolemia, nomeadamente da hipercolesterolemia 
comum ou poligénica, embora nem sempre seja fácil essa diferenciação. 
Foram descritas, em todo o mundo, mais de 1700 mutações diferentes no gene LDLR. Contudo, 
grande parte destas não possuem estudos funcionais, o que impede o diagnóstico definitivo destes 
doentes. 
Em 1999 iniciou-se no Instituto Nacional de Saúde Dr. Ricardo Jorge o Estudo Português de 
Hipercolesterolemia Familiar. Este estudo tem como objetivos a pesquisa de alterações genéticas que 
possam confirmar o diagnóstico clínico de FH em indivíduos da população portuguesa e a determinação 
da prevalência e distribuição da FH em Portugal. Os casos índex são incluídos no estudo caso cumpram 
os critérios adaptados de Simon Broome. Estes critérios categorizam a FH como “definitiva” ou 
“possível”, sendo que a primeira se define, em adultos, por valores de colesterol total acima de 290 
mg/dL ou de colesterol LDL acima de 190 mg/dL, e em crianças, até aos 16 anos de idade, por uma 
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concentração de colesterol total cima de 260 mg/dL ou de colesterol LDL acima de 155 mg/dL, com 
presença de xantomas no doente ou num familiar de primeiro ou segundo grau ou ainda quando existe 
evidência genética de uma mutação num dos 3 genes que cause FH. O diagnóstico “possível” requer a 
presença de níveis de colesterol acima destes valores, valores totais de colesterol acima dos 290 mg/dL 
num familiar de primeiro ou segundo grau e história familiar ou enfarte do miocárdio antes dos 50 anos 
num familiar de segundo grau ou antes dos 60 anos num familiar de primeiro grau. 
Sempre que possível, após a identificação da possível alteração causadora de doença é feito o 
estudo funcional para as variantes de patogenicidade desconhecida, para que o diagnóstico seja o mais 
completo e definitivo possível, contribuindo para uma abordagem terapêutica mais personalizada. 
O principal objetivo deste estudo foi a identificação molecular de variantes genéticas nos genes 
LDLR, APOB e APOE que provoquem dislipidémia. Os doentes referenciados para o Estudo Português 
de Hipercolesterolemia Familiar em 2015/2016 foram o alvo deste projeto. A realização de estudos 
funcionais ao nível do RNA para variantes que afetam o splicing foi também objetivo deste estudo. 
Neste projeto, foram estudados 60 casos índex incluídos no Estudo Português de 
Hipercolesterolemia Familiar. O estudo molecular foi dividido em várias fases: 1. O DNA genómico é 
isolado a partir dos linfócitos do sangue periférico; 2. Os 18 exões, regiões adjacentes e o promotor do 
gene LDLR, parte dos exões 26 e 29 do gene APOB e o exão 4 do gene APOE foram amplificados por 
PCR e sequenciados pelo método de sequenciação direta de Sanger. As sequências foram analisadas em 
computador e comparadas com as sequências de referência de forma a detetar variantes que possam ser 
a causa desta doença, confirmando o diagnóstico clínico; 3. Estudo de grandes rearranjos por Multiplex 
Ligation-dependent Probe Amplification (MLPA).  
Foram realizadas predições in silico para todas as alterações encontradas para prever o seu 
impacto ao nível da proteína. Para as alterações em regiões codificantes foram utilizadas as ferramentas 
PolyPhen-2, SIFT, PROVEAN e Mutationtaster. As ferramentas HSF, NNSSP e FSPLICE foram usadas 
para prever o efeito no splicing causado pelas alterações em regiões intrónicas.  
Quando nenhuma mutação é encontrada nestes três genes e o doente apresenta um fenótipo 
agressivo, procede-se à pesquisa no gene PCSK9 e em todo o gene APOB, representando a quarta fase 
do estudo molecular. Quando são encontradas variantes de patogenicidade desconhecida, são realizados 
estudos funcionais in vitro (fase 5). Embora o estudo completo dos genes PCSK9 e APOB não tenha 
sido realizado durante este trabalho, foram feitos estudos funcionais ao nível do RNA. 
No total, foram identificadas 18 variantes diferentes em 24 destes doentes: 16 no gene LDLR, 1 
no gene APOB e 1 no gene APOE. Apenas 11 destas apresentam estudo funcional. Sempre que existia 
amostra disponível, foi feito também o estudo genético dos familiares, o que permitiu a identificação e 
caracterização genética adicional de 28 indivíduos, num total de 43 doentes com uma alteração 
possivelmente patogénica. Entre estas mutações encontram-se 3 nonsense, 12 missense e 3 que 
possivelmente afetam o splicing. Uma destas mutações foi descrita, pela primeira vez, em Portugal neste 
projeto. A análise de grandes rearranjos não revelou alterações deste tipo no grupo em estudo. 
A confirmação dos efeitos causados ao nível do splicing foi feita para duas das três alterações 
de splicing encontradas no gene LDLR durante este projeto. Para tal, recorreu-se ao isolamento das 
células mononucleares do sangue periférico dos doentes e à extração do RNA utilizando o RNeasy® 
Mini Kit (Qiagen). Após retrotranscrição para cDNA e amplificação da zona a estudar utilizando primers 
específicos, as bandas em gel de agarose foram analisadas e os fragmentos foram sequenciados. As duas 
alterações em causa levam ao skipping de exões e ao aparecimento de codões stop prematuros: no caso 
da alteração c.1060+1G>A, a inativação do donor site no intrão 7 resulta no skipping do exão 7; a 
alteração no último nucleótido do exão 16 (c.2389G>A) leva ao aparecimento de um novo acceptor site 
e, consequentemente, ao skipping do exão 16. 
A FH é caracterizada por níveis elevados de colesterol plasmático desde a nascença. Por isso, é 
de extrema importância que o diagnóstico seja feito o mais cedo possível, principalmente em idade 
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pediátrica para que estas crianças recebam acompanhamento médico personalizado durante toda a vida, 
prevenindo o aparecimento de DCV prematura, permitindo, assim, uma melhor e maior esperança de 
vida. No entanto, é necessária uma maior divulgação da doença, principalmente junto do corpo clínico 
dos hospitais e centros de saúde assim como junto do público em geral. Só após a identificação clínica 
se pode realizar o estudo genético para comprovar a doença e o doente pode então receber 
acompanhamento e tratamento personalizado.  
 
Palavras-chave: Hipercolesterolemia familiar, LDLR, diagnóstico molecular, mutações de splicing 
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ABBREVIATIONS 
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ACAT2  Acyl-coenzyme A type 2 
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ApoAI   Apolipoprotein A I 
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SDS  Sodium Dodecyl Sulfate 
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TG Triglycerides 
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1 INTRODUCTION 
1.1 Coronary Heart Disease and Atherosclerosis 
Cardiovascular disease (CVD) affects the normal function of the heart and blood vessels. Ischemic 
heart disease (myocardial infarction and angina), cerebrovascular disease and heart failure are the 
principal categories. [1] Most cardiovascular diseases can be prevented by addressing social 
determinants of CVD such as tobacco use, unhealthy diet and obesity, physical inactivity and harmful 
use of alcohol. Other risk factors as hypertension, diabetes, stress and dyslipidaemia can also increase 
the probability of having premature CVD. [2] 
Atherosclerosis is a slowly progressive disease of arteries that begins in childhood and does not 
manifest until middle-age or later. [1] It is an inflammatory disease, resulting from infection agents, 
smoking or high plasma concentration of lipoproteins as low-density lipoproteins (LDL), forming 
deposits in the inner wall of the arteries called atherosclerotic plaques. [3] 
CVD remains the most common cause of death globally. [4] Since, in most cases, coronary heart 
disease (CHD) and atherosclerosis due to hypercholesterolaemia can be prevented, it is important to 
identify the individuals at risk and discover the cause of hypercholesterolaemia so they can be properly 
treated decreasing, this way, the CV mortality. 
 
1.2 Lipoproteins and Cholesterol  
A lipoprotein is a biochemical assembly that contains both proteins and lipids which carry the 
cholesterol in the bloodstream.  
Cholesterol is an essential constituent in eukaryotic cell membranes, where it modulates fluidity 
and maintains the barrier between cell and environment. Furthermore, it is used for the manufacture of 
steroid hormones, vitamin D2 and bile acids. [2] It can be derived either from the intestinal absorption 
of dietary cholesterol, through the intestinal epithelial cells, or from synthesis de novo within the body. 
[5] In animal cells, cholesterol is biosynthesized through the mevalonate pathway that generally takes 
place in the endoplasmic reticulum (ER) of hepatic cells. [6] The enzyme Hydroxymethylglutaryl-CoA 
(HMG-CoA) reductase catalyses the limiting step in cholesterol synthesis. Hence, it has been a target 
for cholesterol-lowering drugs. [7] 
Due to cholesterol insolubility in water, it cannot be readily mobilized when it gets accumulated, 
for example, within the wall of an artery, which can lead to the formation of atherosclerotic plaques 
leading to myocardial infarction and strokes. [2] Multicellular organisms solved the problem of 
cholesterol transport, both dietary and synthesized, by converting it into cholesteryl esters and packing 
it in the hydrophobic cores of plasma lipoproteins. This conversion is predominantly catalysed by the 
lecithin cholesterol acyltransferase (LCAT) in the peripheral tissues. [8] In the intestinal lumen, dietary 
cholesterol absorbed by enterocytes is esterified by acyl-coenzyme A: cholesterol acyltransferase type 
2 (ACAT2). [9]   
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1.2.1 The Lipoprotein Pathways 
The pathways of lipoprotein metabolism can be divided into four. 
1.2.1.1 The Exogenous Pathway 
In the dietary fat transport by the exogenous pathway, dietary triglycerides and cholesterol are 
processed in the intestinal lumen, absorbed, and packaged in the intestinal epithelial cell as nascent 
chylomicrons (90% of triglycerides and 3% of cholesterol). [10, 11] After exocytosis to the intestinal 
lymph, these lipoproteins acquire apolipoprotein E (apoE) from circulating high-density lipoproteins 
(HDL) and apolipoprotein C II (apoCII) which is a required co-factor of the enzyme Lipoprotein Lipase 
(LPL). [10] During lipolysis, the newly formed cholesteryl-ester enriched chylomicron remnants, lose 
80-90% of triglyceride content and are removed from the bloodstream by receptors that recognize apoE. 
[12] After endocytosis, the cholesterol and triglycerides are hydrolysed in lysosomes, and the released 
cholesterol can be used to form bile acids, esterified and stored in the cell or used to downregulate HMG-
CoA reductase. [13] 
 
1.2.1.2 The Endogenous Pathway 
By contrast, the endogenous pathway, which is responsible for the majority of cholesterol in 
circulation, requires de novo synthesis of cholesterol by the liver. [14] This results in secretion of nascent 
very low-density lipoproteins (VLDL) composed of triglycerides (70%), cholesterol (10%) and 
apolipoprotein B (apoB). [15] Like chylomicrons, circulating VLDL is hydrolysed by LPL resulting in 
VLDL remnants named IDL (intermediate density lipoprotein) particles that release free fatty acids. IDL 
particles can be cleared from the plasma by the hepatic LDL receptors (LDLR) that bind apoE. [16] The 
LDL formation (10% of triglycerides and 26% of cholesterol) occurs in the circulation from lipolysis of 
IDL and is accompanied by further loss of triglycerides, phospholipids and by the loss of apoE. Only 
apoB-100 is retained and constitutes the ligand for the LDLR. [14] 
 
1.2.1.3 The LDL Receptor Pathway 
LDL is the most abundant cholesterol-carrying lipoprotein in human plasma, being responsible 
for its delivery to all tissues. [17] Each LDL particle has a highly hydrophobic core consisting of 
polyunsaturated fatty acid known as linoleate and molecules of cholesteryl ester. This core is surrounded 
by a polar phospholipid coat and a single large protein: apoB. [18, 19] 
LDL receptors are located on the cell surface, mainly in the liver, and specifically bind to apoB 
on the surface of the LDL (see Figure 1.1). [2, 20] The resulting receptor–ligand complex is then 
internalized by endocytosis forming a coated endocytic vesicle. [21] The endocytosis of LDLR is 
facilitated by LDL Receptor Adaptor Protein 1 (LDLRAP1). Due to the acid pH created by ATP-driven 
proton pumps, the LDLR separates from the LDL. [22] The receptor is recycled to the cell surface, 
whereas the LDL particle is degraded in the lysosomal compartment. The cholesterol esters present in 
the LDL particles are hydrolysed, the cholesterol is released and can be used for the numerous cellular 
functions listed before or stored in the form of cytoplasmic cholesteryl ester droplets until further use 
by the cell. Each cycle takes 10 minutes and LDLR has a 20-hour lifespan. [2] 
LDLR also has affinity to proprotein convertase subtilisin/kexin type 9 (PCSK9) [23], secreted 
from hepatocytes. When present in the endocytic vesicle, binds the LDLR–LDL complex extracellularly 
and prevents it from dissociating, thus targeting the whole complex for degradation in the lysosomal 
compartment acting as a modulator of the LDLR pathway. [21, 24]  
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Figure 1.1 The LDL receptor pathway. On the left: LDLR synthesis occurs in the ER, undergoes extensive glycosylation in 
the Golgi apparatus and it is transported to the cell surface, where specifically binds to apoB in LDL particles. LDL is 
internalized by receptor-mediated endocytosis and the complex dissociates inside the endosome. The receptor is recycled to 
the cell surface and the LDL particle is degraded into the lysosome. On the right: PCSK9 is synthesized and excreted, binds to 
LDLR–LDL complex extracellularly, preventing the complex dissociation, leading to its degradation in the endosomal 
compartment. Adapted from [25] 
 
1.2.1.4 The HDL Reverse Cholesterol Transport Pathway 
This pathway provides a way for cholesterol, which cannot be metabolized by peripheral tissues, 
to move from these tissues back to the liver for excretion, maintaining the cholesterol homeostasis. [15] 
After the uptake of cellular cholesterol by the high-density lipoproteins (HDL), the cholesterol is 
esterified by LCAT. The liver captures the HDL cholesterol esters being here metabolized and excreted 
in the bile. [26]  
 
1.3 Familial Hypercholesterolaemia 
Genetic defects in genes codifying proteins involved in these lipoprotein pathways and the 
interaction between these variants with environmental factors, can lead to lipid disorders. Different 
inherited diseases of lipoprotein metabolism have been described and, for some of them, it has been 
possible to discover the gene involved. For example, if the LDLR pathway performance is compromised 
by a genetic defect in genes codifying one of the proteins, for example, LDLR or LDLRAP1, it can 
result in lipid disorders as Familial Hypercholesterolaemia (FH) or Autosomal Recessive 
Hypercholesterolaemia (ARH), respectively. The fundamental biological and cholesterol regulatory 
mechanisms related with cholesterol have being elucidated with the study of FH. 
Familial Hypercholesterolaemia (FH) is a common autosomal dominant genetic disease clinically 
characterised by high levels of low-density lipoprotein cholesterol (LDL-C). LDL-C deposits in the 
tissues leads to the accumulation in tendons and arteries causing external manifestations, such as 
tendinous xanthomas and corneal arcus. [27] More importantly, LDL-C deposits in arteries can lead to 
premature atherosclerosis and increasing risk of premature CHD. [28] 
FH exists in two forms: heterozygous (heFH) and homozygous (hoFH) form. HeFH is more 
common and less severe with a frequency, in most European countries, between 1/200 and 1/500; FH is 
very rare in the homozygous form, with a frequency of 1:300,000 to 1:1,000,000 in the general 
population. [16, 29]  
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1.3.1 Molecular Pathways That Cause Familial Hypercholesterolaemia 
FH most frequently results from loss-of-function mutations in the LDLR gene representing 
>90% of the FH cases worldwide. [30] Mutations in this gene can affect any domain of the LDLR 
protein and result in: impairment in binding to the LDL particle, failure to internalize into the cell after 
binding, alteration in the transport to Golgi or to the plasma membrane, alteration in the recycle 
mechanism or a complete absence of the LDLR gene. [31, 32] Defects resulting from LDLR mutations 
lead to diminished catabolism of LDL-C, resulting in elevated plasma levels. 
Mutations in APOB or PCSK9 genes are also associated with FH, but they are less frequent. 
[31] A mutation in the APOB gene disables LDL-C from binding to the LDLR and leads to elevated 
LDL-C in the circulation. [33] PCSK9 is involved in the regulation of LDLR, targeting the LDLR for 
lysosomal degradation. [24] Loss-of-function mutations in this gene increase the number of LDLR on 
the cell surface which decrease the LDL-C levels, causing hypocholesterolaemia. [34] For this, recent 
studies are focusing on the potential of PCSK9-inhibiting compounds as a therapeutic target for 
dyslipidaemias. [35-36] On the other and, gain-of-function mutations in the PCSK9 gene cause 
hypercholesterolaemia through higher activity of the LDLR-degrading function of PCSK9 with 
consequently increased plasma LDL-C plasma levels. [37-40] 
The clinical phenotype resulting from these mutations is variable with APOB mutations being 
the least severe of the three. [41] 
The distribution pattern of APOE polymorphisms affects the affinity to lipoprotein receptors 
and, consequently, the clearance of dietary fat from the blood. [42] E2, E3 and E4 are common protein 
isoforms encoded by three different alleles, ε2, ε3, and ε4. [43, 44] Two SNPs determine these isoforms: 
c.388C>T and c.526C>T. ApoE from VLDL, chylomicrons, and chylomicron remnants bind to specific 
receptor cells in the liver. Carriers of the ε2 allele are less efficient in transferring VLDLs and 
chylomicrons from the blood plasma to the liver due to its binding properties. [42] By contrast, carriers 
of the ε3 and ε4 alleles are more efficient in this process. While apo E4 and E3 bind with approximately 
equal affinity to lipoprotein receptors, apo E2 binds with less than 2 percent being associated with low 
cholesterol catabolism and hypertriglyceridemia in heterozygotes, since it can impair triglyceride 
hydrolysis, and type III hyperlipoproteinemia in homozygotes. [45] 
The extremely rare recessive form of hypercholesterolaemia is ARH, caused by mutations in 
the LDLRAP1 gene. [46] In ARH, the internalization of the ligand-receptor complex cannot occur 
resulting in impairment of LDL-C catabolism and increased LDL-C levels. [47] 
 
1.3.1.1 LDL Receptor Gene and Protein 
The LDLR gene, located on the distal short arm of chromosome 19, is comprised of 18 exons and 
17 introns. [48] This gene encodes the LDLR, a cell surface glycoprotein, responsible for the binding 
and uptake of plasma LDL particles and plays a critical role in maintaining cellular cholesterol 
homeostasis. [49] It is synthesized in the rough endoplasmic reticulum (ER), processed in the Golgi 
apparatus, reaching the mature form, and transported to the cell surface (see Figure 1.1). [21] Despite 
the ubiquitous expression of LDLR, it is largely produced by the liver and expressed on the surface of 
hepatocytes. [2] 
The 18 exons of LDLR gene encode five structural domains in the protein: three extracellular and 
two intracellular domains (see Figure 1.2). [50] Exon 1 codes for the signal sequence that directs the 
receptor from ribosomes to the ER membrane. Exons 2-6 encode the ligand binding domain, containing 
the binding for apoB, present in LDL, and apoE, present in VLDL and chylomicrons. The second domain 
is encoded by exons 7-14 and shares homology with a portion of the extracellular domain of the 
Epidermal Growth Factor (EGF) precursor. This domain is involved in the release of bound lipoproteins 
at low pH in the endosome. [22] Exon 15 encodes a domain that serves as an attachment site for O-
linked carbohydrate chains. [51] The transmembrane domain is encoded by exon 16 and the 5’-end of 
5 
 
exon 17, and anchors the protein to the cell membrane. The last protein domain is a COOH-terminal 
cytoplasmatic tail encoded by the rest of exon 17 and exon 18. This domain is responsible for clustering 
the receptor in coated pits, allowing the internalization by receptor mediated endocytosis. [51, 22] 
Changes in the codifying sequence of LDLR might cause serious impact at the protein level and, 
consequently, in the LDLR pathway leading, eventually, to increase or decrease of cholesterol levels in 
circulation. 
 
 
 
 
 
 
 
 
 
Figure 1.2 The LDLR gene and protein. (A) The LDLR gene: exons are shown as vertical dark bars, numbered underneath. 
Single exons or groups of exons (indicated by horizontal arrows) encode the different domains of the LDL receptor protein: 
the ligand binding domain, the EGF precursor-like domain, the O-linked sugars domain (OS), the membrane spanning domain 
(MS) and the internalization signal domain. (IS) (B) The number of point mutations in each exon or domain (boxed) that have 
been found in patients with familial hypercholesterolaemia worldwide. Adapted from [41] 
 
1.3.2 LDLR Variants 
Mutations in the different domains have distinct impact on LDLR structure and function. [2] 
Nevertheless, the simple detection of a variation in the coding sequence of FH-causing genes does not 
confirm the molecular diagnosis of FH. [52] 
Functionally, the LDLR mutations have been classified into five classes: null (produce no 
detectable protein), transport-defective (complete or partial failure in LDLR transport between the ER 
and the Golgi apparatus), binding-defective (the receptor in the cell surface fail to bind LDL), 
internalization-defective (receptors are unable to cluster in clathrin-coated pits and thus do not 
internalize LDL) and recycling-defective (LDLR do not release the ligands in the endosome and cannot 
be recycled to the cell surface). [48] 
Some variants can be promptly classified as pathogenic if they alter the correct 
synthesis/structure of the protein, usually translated in a truncated protein, without function, that would 
possibly be degraded by the cell. These variants include nonsense mutations leading to the occurrence 
of a premature stop codon, large rearrangements and insertions or deletions causing frameshift. [32] The 
pathogenicity of missense variants (the most common FH-causing mutations), deletions or insertions in 
frame, synonymous variants and intronic variants with a possible effect on splicing should be assessed 
with functional studies for an accurate FH genetic diagnosis. [53, 54]    
 
1.3.3 Functional Studies 
Although only few variants have been described in APOB and PCSK9, more than 1700 
different alterations in the LDLR gene have been described worldwide. 
(http://www.ucl.ac.uk/ldlr/LOVDv.1.1.0 and http://www.hgmd.cf.ac.uk/ac/index.php) However, the 
functional studies for the majority of these variants, have not been performed, representing a serious 
problem for FH diagnosis. [55, 56] Only patients identified with variants previously described as 
pathogenic would have a definite diagnosis of FH, as the variants found can justify and confirm the 
clinical diagnosis.  
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Nonsense mutations and large rearrangements, usually, do not require a proof of their 
pathogenicity due to their evident effect in the protein.  For missense and splicing alterations, the 
assessment by functional studies of the effect in the protein is mandatory for the genetic diagnosis of 
FH. 
In the scope of the Portuguese FH Study, 44 functional studies have been performed. 
 
1.3.3.1 Missense Variants 
The human genome contains frequent single-basepair variants, referred as single nucleotide 
polymorphisms (SNPs) that may or may not cause a genetic disease. A missense variant is a point 
mutation that occurs in protein coding regions in the genome resulting in an amino acid substitution at 
the protein. It might affect gene function through their effect on the structure, folding or stability of the 
protein product. [57] The effect of a missense alteration also depends on the evolutionary conservation 
of an amino acid or nucleotide, the location and context within the protein sequence. [58] Consequently, 
the possible disease-association of missense variants is difficult to predict. Several in silico prediction 
software are available to predict the impact of a missense alteration. [58] However, most tools tend to 
have low specificity, overpredicting the missense alterations as deleterious. [59] This emphasizes the 
importance of functional studies to assess their real effect on the protein.  
During the Portuguese FH Study, 31 missense disease causing variants were found, being the 
most common cause of FH. 
 
1.3.3.2 Splicing Variants 
Generally, synonymous variants are assumed to be “silent”. However, they may disrupt normal 
splicing or mRNA folding and stability, which may affect normal peptide synthesis. They can also affect 
the codon usage leading to differences in codon adaptation to tRNA pools and, consequently, influencing 
the speed of translation elongation or transcription/gene expression. The same thought can be applied to 
missense mutations in introns which may contain splicing regulatory regions. Variations in these 
elements, including splice donor (GT), acceptor sites (AG) and exon splice enhancer (ESE) elements, 
can result in complete or partial skipping of the exon, retention of the intron or the introduction or 
activation of a new splice site. [60] Nevertheless, nucleotide substitutions in less conserved positions 
can cause splicing defect in some but not all cases. Accordingly, RNA studies are required to determine 
if an incorrect splicing effect is present.  
Approximately 258 different mutations have been identified in the scope of the Portuguese FH 
study, 13 of which cause splicing alterations. Characterization of these splicing variants and 
quantification of transcripts can lead to the identification of new drug targets and a more precise 
medicine. 
  
1.3.4 Diagnosis of Familial Hypercholesterolaemia 
Familial hypercholesterolaemia is underdiagnosed and undertreated worldwide, particularly 
among children. [61] FH patients present high levels of plasma cholesterol since birth and develop 
premature CHD. Therefore, an early diagnosis of FH is crucial to prevent the consequent morbidity and 
mortality from premature CHD in these patients. FH diagnosis comprise a combination of family history 
of CHD, clinical signs as xanthomas and cholesterol levels. Secondary causes as diabetes, 
hypothyroidism, hepatic and renal diseases, should be excluded for the diagnosis. [21] There are 
different FH clinical criteria to diagnose index cases. The most commonly used are the USMEDPED 
(Make Early Diagnosis to Prevent Early Death), [62] the UK (Simon Broome) [63] and the Dutch Lipid 
Clinic. [64] Nevertheless, only genetic testing may give a definite diagnosis of FH by detection of a 
pathogenic variant. 
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1.3.5 Treatment 
FH patients have increased LDL-C levels over a lifetime and, consequently, develop CHD at 
significantly earlier ages and at a greater frequency than the general population. [65] To prevent this, 
treatment should be implemented immediately once the diagnosis of FH is achieved. Reducing 
cholesterol levels and controlling risk factors as smoking, diet and physical activity are the initial 
treatment strategies. [66]  
Several lipid-lowering drugs are currently available. HMG-CoA reductase inhibitors, known 
as statins, inhibit the production of endogenous cholesterol and increase the expression of LDLR thereby 
increasing LDL uptake and catabolism. This results in the reduction of LDL-C between 20-45%, 
depending on the dosage. [67] Nonetheless, statins do not lower LDL significantly in hoFH 
patients, who have null variants in both copies of the LDLR. [68] 
Ezetimibe, a drug that inhibits cholesterol absorption, reduces the amounts of dietary 
cholesterol that reach the liver. [69] Used as monotherapy, ezetimibe cause a reduction of almost 20% 
in LDL-C. [70] However, it can also be coadministraded with statins which will decrease LDL 
cholesterol by 60–70%. [29] Since ezetimibe is usually better tolerated, it may become the first choice 
for heFH patients who do not tolerate high doses of statins. [64] 
Recently, plant sterols and stanols have been demonstrated to exert a beneficial effect on 
lowering LDL-C concentrations through inhibition of intestinal cholesterol absorption, even in the 
presence of diets with low cholesterol content. [71] The administration of plant sterols and stanols is 
common in heFH children and reduce LDL-C by 10 and 15%, respectively. [72, 73] 
Plasma levels in hoFH patients or in heFH patients resistant to lipid-lowering drugs can only 
be lowered with LDL apheresis, an extracorporeal procedure to remove the LDL-C from the blood. 
New LDL lowering drugs have been discovered with the advances in genetic-based 
pharmacology: monoclonal antibodies targeting PCSK9, anti-sense oligonucleotides targeting apoB and 
cholesteryl ester transfer protein inhibitors. [29] Nevertheless, further studies are required to determine 
the long-term safety of these therapeutic measures and their efficacy in preventing CHD. [35] 
 
1.4 Portuguese FH Study 
In 1998, the World Health Organization (WHO) recommended universal screening for FH. Hence, 
in 1999, the Portuguese FH study was established at the National Institute of Health. This study was 
designed to identify the genetic cause of hypercholesterolaemia in individuals with a clinical diagnosis 
of FH, cascade screening in relatives of the affected index patients and to determine the prevalence and 
distribution of FH in Portugal. [74] Index patients are included in this study using an adapted Simon 
Broome (SB) criteria.  [56] 
In the last 16 years, a genetic defect was identified in 663 patients, representing 3.32% of the cases 
estimated to exist in Portugal. The implementation of the molecular study of this disorder in Portugal, 
promotes the early identification, in these patients and their relatives, leading to a correct counselling 
and decreasing their cardiovascular risk.  
This study implies a biochemical and a genetic diagnosis of FH, performed in four phases and an 
optional fifth phase, as schematically represented in Figure 1.3.   
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Figure 1.3 Phases of molecular study in the Portuguese FH study. Adapted from [56] 
 
When a putative disease-causing variant is identified in an index case, a cascade screening is 
performed if samples of relatives are available. The cascade screening has been proved to be the most 
cost-effective method of identification and has an important role in identifying young patients. [75] 
Early identification of FH and the implementation of preventive measures and correct treatment can 
prevent premature CHD. 
 
1.5 Aim of the Present Work 
Although the Portuguese FH Study has been implemented in Portugal in 1999 and 
more than 800 families have been enrolled [56], only 3.32% of the cases estimated to exist in Portugal 
were identified. The extent of underdiagnosis and undertreatment of individuals in the Portuguese 
population with FH is alarming. 
In order to improve the identification of individuals at risk, the main aim of this project is to perform 
the molecular identification of genetic variants causing dyslipidaemia in LDLR, APOB and APOE genes, 
in patients referred to the Portuguese FH Study in 2015/2016 with a clinical diagnosis of FH. Different 
in silico analysis and functional studies of putative splicing variants will be performed to achieve this 
aim.  
  
Biochemical Study 
Lipid 
Profile 
Total cholesterol; LDL-C; HDL-C; Triglycerides; Apolipoprotein B; 
Apolipoprotein A1; Lipoprotein (a) 
Molecular Study 
DNA extraction. Screening for the common mutations in APOB gene, analysis 
of LDLR gene and exon 4 of APOE gene 
Identification of large rearrangements in the LDLR gene using MLPA 
technique 
Screening of PCSK9 gene (only performed if no mutation was found in phases 
I and II) 
APOB gene: study of promoter, all exons and flanking 
regions in selected patients (only performed if no mutation was found in phases 
I, II and III) 
Functional in vitro studies of LDLR, APOB or PCSK9 alterations identified 
with unknown pathogenicity  
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2 METHODS 
2.1   Patients recruitment 
2.1.1 Study Population  
Patients were recruited, all over the country, for the Portuguese Familial 
Hypercholesterolaemia Study, whose protocol and database have been approved by the National 
Institute of Health Ethics Committee and the National Data Protection Commission, respectively. A 
total of 60 index patients (35 adults and 25 children) and 28 affected and unaffected relatives where 
included in this study. Written informed consent was obtained from all participants before their inclusion 
in the study. Index patients were selected following an adaptation of the Simon Broome criteria for FH. 
[76] The Simon Broome criteria categorises familial hypercholesterolaemia as “definite” or “possible”. 
“Definite” familial hypercholesterolaemia is defined as total cholesterol (TC) concentration >290 mg/dL 
or LDL-C concentration >190 mg/dL for adults and TC concentration >260 mg/dL or LDL-C 
concentration >155 mg/dL for children under 16, plus tendon xanthomas in the patient or a first or 
second degree relative and genetic evidence of mutation in LDLR or APOB genes. A “possible” 
diagnosis of familial hypercholesterolaemia requires cholesterol above these values, plus a family 
history of either a myocardial infarction before age 50 in a second degree relative or before age 60 in a 
first degree relative or a raised TC concentration >290 mg/dL in a first or second degree relative. More 
recently, newly determined cut-off points for lipid biomarkers as apoB/apoA1 ratio ≥0.68 have been 
conjugated with the Simon Broome criteria to improve children identification, especially trough clinical 
differentiation between monogenic and polygenic dyslipidaemia. [77] 
 
2.1.2 Blood Samples Collection 
For each index case and respective relatives, fasting blood samples were collected in order to 
perform DNA extraction (3 x 2,7 mL in EDTA tubes) and biochemical determination (7,5 mL in serum 
tube). A confidential identification number was assigned for each sample and all the information 
concerning the patients was registered in a confidential database, according to legal requirements. 
 
2.1.3 Biochemical Characterization 
The biochemical parameters, including total cholesterol (TC), LDL cholesterol (LDL-C), HDL 
cholesterol (HDL-C), triglycerides (TG), apolipoprotein AI (ApoAI), apolipoprotein B (ApoB) and 
lipoprotein (a) (Lp(a)), were determined at the Unidade Laboratorial Integrada at INSA, using an 
autoanaliser Cobas Integra 400 plus (Roche) by enzymatic, colorimetric and immunoturbidimetric 
methods. 
 
2.2 Molecular Biological Techniques 
2.2.1 Genomic DNA extraction 
Genomic DNA was isolated from peripheral blood EDTA samples, using an adaptation of the 
protocol described in D.K.Lahiri et al. (1991). For index cases, DNA extraction was performed for all 
collected tubes, in independent days, providing different DNA samples for diagnosis confirmation. The 
proportion of each reagent to mL of blood is presented in Appendix I, Table A I.1. Whole blood was 
homogenised and transferred into a 15 mL falcon tube at which was added equal volume of TKM X-
100 (low salt buffer containing 10 mM Tris-HCl pH 7.6, 10 mM MgC12 and 2 mM EDTA and 25 mL 
of Triton X- 100/L). After mixing by inversion, IGEPAL was also added to lyse the cells and the blood 
was mixed until total solubilisation. The tubes were centrifuged for 10 min at 2200 rpm, at room 
temperature (RT) (centrifuge 5810 R, Eppendorf). The supernatant was poured off and the pellet was 
washed in TKM1 buffer (TKM-X100 without the Triton-X 100) and centrifuged for 10 min at 1600 
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rpm, at RT. After repeating this step once, the pellet was ressuspended in TKM2 (high salt buffer 
containing 10 mM Tris-HC1 pH 7.6, 10 mM KCl, 10 mM MgCl2, 0.4 M NaCl and 2 mM EDTA). After 
addition of SDS 10%, the suspension was mixed and incubated for 10 min at 55°C for protein 
denaturation. Afterward, the whole content was transferred to a 2 mL Eppendorf tube and NaCl 5M (60 
µL for mL of blood) was added for protein precipitation. Once centrifuged for 20 min at 13200 rpm, at 
RT, in microcentrifuge, all the supernatant was transferred to a clean falcon tube and absolute ethanol 
(2.3 mL for 1 mL of blood) was added and gently mixed by inversion, in order to denature and precipitate 
the DNA. The DNA fibrils were removed with a loop and washed with 70% ethanol. When dried, the 
DNA was transferred into an Eppendorf with TE (10 mM Tris-HCL, 1 mM EDTA ph 8.0). 
DNA purity (A260 and A280) and concentration were determined using the NanoDrop ND-1000 
(Thermo Scientific). The quality of DNA was assessed by agarose gel electrophoresis, using 1% agarose 
gel (w/v), prepared with TBE buffer 1x (Invitrogen), with 0.002% of SYBR Safe DNA gel stain 
(Invitrogen) and mixing 1 µL of genomic DNA diluted in bidistilled water with the gel loading die 
(bromophenol blue) to a final volume of 10 µL. The electrophoresis was performed in a Bio-Rad Power 
Pac 3000 equipment for 40 min at 90 Volt, in TBE 1x, and the gel was visualized in a Safe Imager™ 
blue light transilluminator (Invitrogen). 
 
2.2.2 DNA analysis 
The promoter region and the 18 exons plus flanking regions of the LDLR gene were amplified from 
genomic DNA by polymerase chain reaction (PCR) and screened for sequence alterations using Sanger 
sequencing. Screening for the common mutations in the APOB and APOE gene was performed by PCR 
amplification and sequencing fragments of exons 26 and 29 for APOB and exon 4 for APOE. A list with 
the primers used and the distinct annealing temperatures for each exon, as well as the protocol used to 
prepare each PCR mix, are disclosed in Appendix I, table A I.2 and A I.3, respectively. The PCR was 
performed in a T3000 thermocycler (Biometra) using the following cycle conditions: initial denaturation 
for 3 min at 95ºC; 35 cycles of three steps: denaturation for 45 sec at 94ºC, annealing for 30 sec at primer 
specific annealing temperature, and elongation for 1 min at 72ºC; and final extension for 30 min at 72ºC. 
The PCR products were stored at 4ºC.  
All PCR products were assessed by an agarose gel electrophoresis, using 1,5% agarose gel (w/v), 
prepared with TBE buffer 1x (Invitrogen), with 0.002% of SYBR Safe DNA gel stain (Invitrogen) and 
mixing 5 µL of PCR product with the gel loading dye (bromophenol blue) to a final volume of 10 µL. 
The 100bp DNA ladder was used to confirm the approximate size of the PCR products. The 
electrophoresis was performed in a Bio-Rad Power Pac 3000 equipment for 40 min at 90 Volt, in TBE 
1x, and the gel was visualized in a Safe Imager™ blue light transilluminator (Invitrogen). 
 
2.2.3 Automated sequencing 
Before Sanger sequencing, PCR products were purified to remove the excess of primers and dNTPs. 
The enzymatic digestion was performed using two hydrolytic enzymes: Exonuclease I and Shrimp 
Alkaline Phosphatase (SAP), combined in a commercial product named ExoStar (IllustraTM 
ExoStarTM, GE lifesciences). To 2,5 µL of PCR product, 1 µL of ExoStar was added in a reaction tube 
and incubated for 15 min at 37ºC (enzyme optimum temperature) and for 15 min at 80ºC for enzyme 
inactivation. Purification products were stored at 4ºC until further use. The sequencing reaction was 
prepared as follows: 1 µL of primer at 2 ρmol/ µL, 1 or 2 µL of BigDye (Terminator Cycle Sequencing 
Ready reaction kit, Applied Biosystems), depending on fragment length, and bidistilled water were 
added in a reaction tube to a final volume of 9 µL. At last, 1 µL of purified PCR product was added. 
The sequencing reaction was performed in a T3000 thermocycler (Biometra) using the following cycle 
conditions: initial denaturation for 30 sec at 96ºC; 25 cycles of three steps: denaturation for 10 sec at 
96ºC, annealing for 5 sec at 50ºC and elongation for 4 min at 60ºC. Sequencing products were stored at 
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4ºC. The resulting products were sequenced at the Unidade de Tecnologia e Informação (UTI – INSA) 
(3130xl Genetic Analyser, Applied Biosystems). The subsequent ABI sequence files were analysed with 
Staden Package software (version 2.0). Gene mutation nomenclature used in this study follows the 
recommendations of Human Genome Variation Society (www.hgvs.org). The reference sequences used 
were APOB: NM_000384.2; LDLR: NM_000527.4; APOE: NM_000041, where +1 is the A of the ATG 
translation initiation codon of the coding DNA. [78] Variant nomenclature was revised using the 
program Mutalyzer (https://mutalyzer.nl). Whenever an alteration was found, all PCR, assessment and 
sequencing protocols were repeated in a second independent sample of the index case, and the molecular 
study was also performed for the relatives, when samples were available, for confirmation and co-
segregation studies. 
 
2.2.4 Multiplex Ligation-dependent Probe Amplification (MLPA) 
The SALSA® MLPA® kit (probemix P062-C2 LDLR, MRC-Holland, The Netherlands) was used, 
according to the manufacturer's instruction, to search for large rearrangements (duplications or 
deletions) in the LDLR gene. The MLPA protocol is divided in four major steps: sample DNA 
denaturation, probes hybridization, probe ligation and PCR reaction for amplification of ligated probes. 
Fragments were separated by capillary electrophoresis, performed by Unidade de Tecnologia e 
Informação (UTI – INSA) (3130xl Genetic Analyser, Applied Biosystems) and the data was analysed 
using Coffalyser – MLPA analysis tool (MRC-Holland, The Netherlands). 
 
2.2.5 Study of variants affecting mRNA splicing  
2.2.5.1 Isolation of Peripheral Blood Mononuclear Cells (PBMC) 
Peripheral Blood Mononuclear Cells (PBMC) were isolated from fresh blood collected in CPT 
tubes (cell preparation tube with sodium citrate, BD Vacutainer®) by centrifugation for 30 min at 2800 
rpm, at room temperature (18ºC) (separation of PBMC must occur during the first 2 h after collection). 
After PBMC resuspension trough inversion of CPT tube, the upper layer containing plasma and PBMC 
was transferred to a 15 mL falcon tube. The PBMC were obtained by centrifugation for 10 min at 1600 
rpm, 4ºC. The plasma was separated and stored in 2 mL eppendorfs at -80ºC. The mononuclear cells 
(pellet) were then washed with 1 mL of PBS 1X: 1 µL of this cellular suspension was added to 9 µL of 
Trypan Blue (1:10 diluted) and used for cell count, applying the 10 µL in a Neubauer counting chamber; 
the remaining suspension was centrifuged for 10 min at 3000 rpm, 4ºC. The resulted pellet was 
resuspended in 350 µL (<5x106 cells) to 600 µL (≥5x106 to 1x107 cells) of RLT Buffer (Quiagen) (1% 
Mercaptoethanol) with a syringe (27G) to perform cellular lysis.  The lysate was centrifuged, in a 
QIAShredder mini column, for 2 min at 13200 rpm, 4ºC. The tubes were stored at -80ºC until RNA 
extraction.  
 
2.2.5.2 RNA extraction  
Total RNA was extracted with the RNeasy® Mini Kit (Qiagen). After thawing the samples, equal 
volume of ethanol 70% (V/V) (-20ºC) was added to the lysate and then homogenised. The total volume 
was transferred to an RNeasy column and centrifuged for 15 sec at 11000 rpm at 18ºC. The eluted 
volume was poured off. Depending on lysate volume, 350 µL to 500 µL of ethanol 70% (V/V) were 
added to the column and centrifuged as above. The column was transferred to a new collector tube and 
350 µL of RW1 buffer solution was applied right in the centre of the column. After gently mixing by 
inversion, the tube was centrifuged as above and the volume in the collector tube was discarded. For 
one sample, the Mix DNase I was prepared adding 70 µL of RDD buffer to 10 µL of DNase I and gently 
mixing. The 80 µL of this mix were directly applied in the centre of the membrane and incubated at 
room temperature (18ºC - 30ºC) for 15 min. To remove the DNase I, 350 µL of buffer RW1 solution 
were added and the tubes were centrifuged for 15 sec at 11000 rpm, 18ºC. The eluted volume was poured 
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off, 500 µL of RPE buffer solution were mixed in and the centrifugation was performed as in the 
previous step. This step was repeated once and then a new centrifugation in the same conditions was 
performed to remove all RPE buffer. The column was transferred to a new Eppendorf of 1.5 mL and 50 
µL of RNase free water were applied in the centre of the membrane. The tube was centrifuged for 1 min 
at 13000 rpm at 4ºC to elute the RNA. The column was discarded and 6 to 10 µL were removed to an 
Eppendorf and used for quantitative and qualitative analysis of RNA. The remaining volume was 
distributed in aliquots and stored at -80ºC.  
The RNA purity (A260 and A280) and concentration were determined using the NanoDrop ND-
1000 (Thermo Scientific) and quality was assessed by agarose gel electrophoresis, using 1% agarose gel 
(w/v). The gel was prepared with TBE buffer 1x (Invitrogen), with 0.002% of SYBR Safe DNA gel 
stain (Invitrogen) and mixing 5 µL of RNA with the gel loading dye (bromophenol blue) to a final 
volume of 10 µL. The electrophoresis was performed in a Bio-Rad Power Pac 3000 equipment for 40 
min at 90 Volt, in TBE 1x, and the gel was visualized in a Safe Imager™ blue light transilluminator 
(Invitrogen). 
 
2.2.5.3 Reverse transcriptase (RT) reaction and cDNA analysis 
To prepare cDNA, 1µg of RNA was reverse transcribed with High capacity RNA-to-cDNA kit 
from Applied Biosystems, according to the manufacturer's instruction. For the RT mix, 10 µL of RT 
Buffer 2X, 1 µL of enzyme 20X, 1 µg of RNA and DEPC water were added in a reaction tube to a final 
volume of 20 µL. In each reaction, no template control (NTC) and no enzyme control (NEC) were added, 
to ensure that no contaminants were present in the reaction and to determine that any amplification that 
occurs in the sample was derived from the synthesised cDNA and not from genomic DNA or other 
amplicon contamination. cDNAs were stored at -30ºC.  
PCR was performed to amplify LDLR coding sequences. Regions of interest were amplified with 
specific primers designed to evaluate the effect on cDNA of each splicing variant found. A list with the 
primers used, the annealing temperatures and the protocol used to prepare each PCR mix, are disclosed 
in Appendix I, table A I.4 and A I.5. The PCR was performed in a T3000 thermocycler (Biometra) using 
the following cycle conditions: initial denaturation for 2min at 94ºC; 38 cycles of two steps: denaturation 
for 45 sec at 95ºC, annealing for 1min 45 sec at primer specific annealing temperature followed by 
elongation for 7 min at 65ºC and final extension for 30 min at 4ºC. The PCR products were stored at 
4ºC.  
Specific detection of each transcript was accessed by an agarose gel electrophoresis, using 3% 
agarose gel (w/v) with NuSieve™ 3:1 Agarose. The gel was prepared with TBE buffer 1x (Invitrogen), 
with 0.002% of SYBR Safe DNA gel stain (Invitrogen) and mixing 8 µL of cDNA product with the gel 
loading dye (bromophenol blue) to a final volume of 10 µL. The pUC18 DNA Hae III ladder was used 
to confirm the approximate size of the PCR products. The electrophoresis was performed in a Bio-Rad 
Power Pac 3000 equipment for 1h at 50 Volt, in TBE 1x, and the gel was visualized in a Safe Imager™ 
blue light transilluminator (Invitrogen).  
 
2.2.6 In silico Analysis 
When any variant was found in LDLR, APOB or APOE genes, the predicted effects were assessed 
using the following open access software: Polymorphism Phenotyping (PolyPhen-2) [59], Sorting 
Intolerant From Tolerant (SIFT) [79], Protein Variation Effect Analyzer (PROVEAN) [80] and 
MutationTaster [81] for prediction of single nucleotide substitutions. SIFT takes into account 
evolutionary conservation through the use of sequence alignments, while PROVEAN, MutationTaster 
and PolyPhen-2 base their predictions in protein structure/function and evolutionary conservation. 
Human Splicing Finder (HSF) (http://www.umd.be/HSF3/HSF.html) [82], the Nearest-neighbor 
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Secondary Structure Prediction (NNSSP) (http://www.fruitfly.org/seq_tools/splice.html) [83] and the 
FSPLICE (http://linux1.softberry.com/) tools were used for prediction of splicing defects. HSF uses 
position-dependent logic, identifying exonic and intronic motifs. NNSSP is based in neural networks 
combining a sequence similarity matrix with a local structural environment scoring scheme for 
predicting protein secondary structure and FSPLICE (http://linux1.softberry.com/) bases its predictions 
on weight matrices model, which consider the importance of the presence of a determinate nucleotide 
in a specific position. Mutation Taster also predicts a phyloP score, a measurement of evolutionary 
conservation; thus the higher the score, the stronger is the evolutionary conservation for that specific 
nucleotide. Variants were classified as pathogenic, likely pathogenic, benign and likely benign 
according to the American College of Medical Genetics (ACMG) recommendations. [58] When the 
classification is contradictory or if that is not enough points for classification in either category, the 
variant is classified as variant of unknown significance (VUS).  
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3 RESULTS 
3.1 Molecular Diagnosis 
A group of 60 unrelated individuals were studied, 25 children and 35 adults. A total of 28 relatives, 
affected and unaffected, were also studied. A summary of biochemical characterization of patients 
presenting values before medication and clinical characterization of all patients is presented in Table 
3.1. A more detailed characterization including information as age, cardiovascular events and 
medication is presented in Appendix II, Table A II.1. 
 
Table 3.1 Summary of clinical and biochemical characterization.  
 
 TC LDL-C HDL-C TG 
ApoB/ 
ApoA1 
On 
medication 
CHD 
Children 
292 mg/dL 
(n=23) 
214 mg/dL 
(n=23) 
58 mg/dL 
(n=23) 
92 mg/dL 
(n=23) 
0.94 
(n=23) 
52% 
(n=25) 
0% 
(n=25) 
Adults 
346 mg/dL 
(n=19) 
259 mg/dL 
(n=19) 
55 mg/dL 
(n=19) 
156 mg/dL 
(n=19) 
0.98 
(n=19) 
85% 
(n=34) 
49% 
(n=35) 
 
3.1.1 Molecular Study of LDLR, APOB and APOE Genes 
The promotor region, 18 exons of LDLR and adjacent regions, as well as part of exons 26 and 
29 of APOB and exon 4 of APOE were analysed for all index patients. No homozygous patients were 
found in this study. However, 24 individuals were identified as heterozygous for 18 different variants. 
These include 12 missense alterations (1 with unknown effect and 11 causing an aminoacid change), 3 
nonsense alterations resulting in a premature stop codon and 3 putative splice alterations (see Table 3.2). 
All patients included in the study had severe hypercholesterolaemia and family history of high 
levels of cholesterol, 17 had cardiovascular disease and 22 presented family history of CHD. However, 
it was not possible to identify a clear relationship between phenotype and family history with the 
presence or not of a pathogenic variant, supporting the importance of the molecular confirmation of a 
clinical diagnosis. 
Of the 24 index patients with a possible mutation, 12 were children and the other 12 were 
adults (see figure 3.1).  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Summary of molecular diagnosis results. 
 
  
24 patients with a putative mutation: 
22 in LDLR, 1 in APOB and 1 in APOE
36 patients without mutation
60 Possible FH Patients
25 Children 35 Adults
19 hypercholesterolaemic patients 
with a putative mutation: 
18 in LDLR and 1 in APOB
9 normolipidaemic patients without 
mutation
28 Relatives
5 Children 23 Adults
12 Children 12 Adults
13 Children 23 Adults
4 Children 15 Adults
1 Children 8 Adults
Total of individuals identified with a putative mutation: 
24 index cases + 19 relatives = 43 individuals 
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Table 3.2 Variants in LDLR, APOB and APOE genes identified in studied index cases.  
  
NP, not performed. Coseg, co-segregation in studied families: variant carriers/total affected; variant carriers/total non-affected. PSC, premature stop codon. aa change, aminoacid change 
 
 Alteration 
Described by 
Functional 
studies 
 
Coseg 
Patient Location 
Nucleotide 
Change 
Protein                   Domain 
Effect on 
protein 
18 LDLR Exon 1 c.1 A>C p.(?) Signal sequence Unknown [84-86] NP 2/2;0/0 
12 LDLR Exon 3 c.261G>A p.(Trp87*) Ligand binding PSC [86] Yes 3/3;0/0 
28 LDLR Exon 4 c.551G>A p.(Cys184Tyr) Ligand binding aa change [74,87-90] Yes 1/1;0/0 
1,8,20,57 LDLR Exon 4 c.670G>A p.(Asp224Asn) Ligand binding aa change [48,91-92] Yes 7/7;0/3 
39 LDLR Exon 4 c.693C>G p.(Cys231Trp) Ligand binding aa change [93-95] NP 1/1;0/0 
10 LDLR Exon 6 c.862G>A p.(Glu288Lys) Ligand binding aa change [92,96] Yes 2/2;0/0 
33 LDLR Intron 6 c.941-2A>C p.(?) - Splicing [95,97] NP 1/1;0/0 
14,26 LDLR Intron 7 c.1060+1G>A p.Gly314_Glu353del - 
 Skipping of 
exon 7 
[74,98] Yes  3/3;0/2 
21,29 LDLR Exon 9 c.1216C>T p.(Arg406Trp) EGF percursor homology aa change [99,100] Yes 4/4;0/1 
34,50 LDLR Exon 9 c.1291G>A p.(Ala431Thr) EGF percursor homology aa change [90,95,100-104] Yes 3/3;0/2 
37 LDLR Exon 10 c.1374_1375del p.(Arg458Serfs*8) EGF percursor homology PSC [105] NP 3/3;0/0 
58 LDLR Exon 10 c.1432G>A p.(Gly478Arg) EGF percursor homology aa change [48,90,106-108] Yes 1/1;0/0 
6 LDLR Exon 13 c.1886del p.(Phe629Serfs*36) EGF percursor homology PSC [92] NP 1/1;0/1 
25 LDLR Exon 13 c.1897C>T p.(Arg633Cys) EGF percursor homology aa change [109-111] NP 2/2;0/0 
59 LDLR Exon 14 c.2054C>T p.(Pro685Leu) EGF percursor homology aa change [74,107,112-115] Yes 1/1;0/0 
5 LDLR Exon 16 c.2389G>A p.Ala771Valfs*17 Membrane spanning 
Skipping of 
exon 16/PSC 
[90,97,107, 
116,117] 
Yes 4/4;0/0 
19 APOB Exon 26 c.10580G>A p.(Arg3527Gln) Domain 6 aa change [33,118-122] Yes 2/2;0/0 
53 APOE Exon 4 c.487C>T p.(Arg163Cys) α-helix H4 aa change [123,124] NP 1/1;0/0 
  
16 
 
Eighteen different variants were found: 16 in LDLR gene, 1 in APOB and 1 in APOE. Despite 
the fact that 11 of these variants have functional studies previously reported and 2 are nonsense variants, 
considered pathogenic due to the severity of the defect (premature protein termination), in silico 
predictions were performed for all of them (see Table 3.3). The confirmation of the clinical diagnosis 
was only achieved for 19 of 24 index patients (79%) since only 13 variants have proof of its 
pathogenicity.  
The pathogenicity of the remaining 5 variants was not proven until now and so, definite 
diagnosis was not possible for the 5 index patients with these variants (21%):  2 children and 3 adults. 
In children, the 2 missense variants in LDLR, without functional studies, are classified as likely 
pathogenic following ACMG recommendations. In adults, 1 of the 3 variants is a missense variant in 
LDLR likely to be pathogenic, 1 is a putative splicing variant in LDLR classified as pathogenic but with 
no prove of its effect and the last one is a missense variant in APOE described in patients with other 
type of dyslipidaemia, classified by ACMG as VUS.  
Considering all alterations found, the positive genetic rate was 48% in children and 34% in 
adults. These values decrease if only proved pathogenic mutations are considered (40% in children and 
26% in adults). No mutation was found in 36 patients in the three studied genes, representing 60% of 
the index cases studied here. 
Several variants detected in this study were first described in other populations (see Table 3.1), 
apart from variant c.1060+1G>A, first described in Portugal and already functionally characterized. 
For index patients with an identified variant, the cascade screening was performed for their 
relatives if samples were available. A total of 28 relatives were studied allowing the identification of 
another 17 definite FH patients (4 children and 13 adults) and 2 possible FH patients.  
 
3.1.1.1 LDLR Gene  
Of the 16 variants found in LDLR gene, 12 are pathogenic: 10 were previously proved to be 
pathogenic by functional studies and 2 are nonsense variants considered pathogenic due to their effect 
(see Table 3.4). Concerning their location, the EGF precursor homology domain has the largest number 
of variants detected in this study, as shown in Figure 3.2. Two of the variants found in these patients are 
present in the noncoding sequence. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 The LDLR gene and variants found in each domain. (A) The LDLR gene and protein domains: ligand binding 
domain, EGF precursor-like domain, O-linked sugars domain (OS), membrane spanning domain (MS) and internalization 
signal domain (IS). (B) The number of point mutations in each domain that have been found in patients with clinical diagnosis 
of familial hypercholesterolaemia during this study. Adapted from [41] 
 
3.1.1.1.1 Missense Variants in LDLR 
The majority of the variants identified in the studied patients are missense mutations localized in 
the EGF precursor homology and ligand binding domains. Only 7 of the 10 missense mutations found 
in LDLR gene were previously proved to be pathogenic.  
The effect of c.1 A>C alteration is unknown. Since this variant occurs in the first codon of exon 
1, corresponding to the ATG codon start, it is thought to be a missense variant without protein 
production. It is classified as probably pathogenic following ACMG recommendations and overall in 
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silico results in a non-concordant prediction. The remaining 9 alterations cause an aminoacid change in 
the protein and all of them are predicted to be pathogenic by overall in silico software packages. 
p.(Cys184Tyr), p.(Asp224Asn), p.(Cys231Trp) and p.(Glu288Lys) are variants in the exon 4 and 6 of 
LDLR, corresponding to the ligand binding domain of the protein. p.(Arg406Trp), p.(Ala431Thr), 
p.(Gly478Arg), p.(Agr633Cys), p.(Pro685Leu) occur in the EGF precursor homology domain. None of 
these missense mutations were predicted to affect splicing. According to ACMG classification, 4 of 
them are classified as pathogenic, 5 as likely pathogenic and 1 as VUS (see Table 3.3).  
 
3.1.1.1.2 Nonsense Variants in LDLR 
Three nonsense variants have been found: p.(Trp87*) results in a premature stop codon in the 
ligand binding domain; p.(Arg458Serfs*8) and p.(Phe629Ser fs*36) are frameshift mutations caused by 
a deletion changing the reading frame and resulting in a premature stop codon. 
  
3.1.1.1.3 Splicing Variants in LDLR  
Three putative splicing variants were found in the index patients analysed.  
c.941-2A>C, p(?)    
A blood sample for the RNA study was not available for the patient with this alteration. However, 
Sanger sequencing of patient’s DNA revealed a deletion of the acceptor site of exon 7, probably causing 
retention of part or the entire intron 6. The variant is classified as pathogenic by overall in silico 
predictions with a reduction or complete absence of the acceptor site. ACMG also classifies it as 
pathogenic. 
c.1060+1G>A, p.Gly314_Glu353del 
Sanger sequencing of patients’ DNA with this variant revealed a disruption of the donor site in 
intron 7. This is expected to cause total skipping of exon 7 (see Figure 3.3). The splice site scores showed 
a reduction from 100% for the natural donor site to 69 or 0% for the variant site. Blood samples from 
these patients were not available for the RNA study. However, it was possible to have a blood sample 
from another patient, with the same alteration, for the study of the mutation mechanism.  
A fragment of mRNA encompassing the region encoding exons 5 to 9 was amplified and the agarose 
gel electrophoresis of the product revealed two fragments: the expected fragment of 497 bp and a smaller 
fragment of approximately 377 bp, lacking the exon 7, confirmed by Sanger sequence (see Figure 3.3).  
 
  
 
 
 
 
 
 
 
 
 
                                 
 
 
 
 
 
 
Figure 3.3 Functional study of c.1060+1G>A alteration. A. Schematic effect of c.1060+1G>A mutation in intron 7 
of LDLR gene, resulting in exon 7 skipping.  B. Comparison between DNA electropherograms of patient with 
c.1060+1G>A alteration and normolipidaemic control. C. Gel-electrophoresis of amplicons encompassing exons 5 to 9. 
One index case of the Portuguese FH Study with c.1060+1G>A alteration is shown (Y). A normolipidaemic individual was 
used as negative control (NC). No enzyme control (NEC) and no template control (NTC) were also included in the experiment. 
pUC18 DNA Hae III Digest was used as ladder (M). The size (in base pairs) of each fragment is indicated on the left side. 
B. C. 
A. 
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c.2389G>A, p.Ala771Valfs*17  
Sanger sequencing of patients’ DNA with this variant revealed the creation of a new acceptor site 
in the end of exon 16 (see Figure 3.4). Human Splicing Finder predicted a splice site score of 150% for 
the variant site when compared to the 100% of the normal acceptor site. On the other hand, FSPLICE 
predicted a considerable reduction (<88%) of the donor splice site score from 100% to 52% for the 
variant site. 
A fragment of mRNA encompassing the region encoding exons 15 to 18 was amplified from 
samples of the index patient and three relatives by RT-PCR. The agarose gel electrophoresis of the 
product revealed two fragments: the expected fragment of 381 bp and a smaller fragment of 
approximately 303 bp, lacking the exon 16, confirmed by Sanger sequence (see Figure 3.4). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Functional study of c.2389G>A alteration. A. Schematic effect of c.2389G>A mutation in intron 16 of LDLR 
gene, resulting in exon 16 skipping. B. Comparison between DNA electropherograms of patient with c.2389G>A 
alteration and normalipidaemic control. C. Gel-electrophoresis of amplicons encompassing exons 15 to 18. Four samples 
are shown:  the index case (5) and three relatives identified by cascade screening: the mother 5(a), the sister 5(b) and the 
grandfather 5(c). A normolipidaemic individual was used as negative control (NC). No enzyme control (NEC) and no template 
control (NTC) were also included in the reaction. pUC18 DNA Hae III Digest was used as ladder (M). The size (in base pairs) 
of each fragment is indicated on the left side. 
 
3.1.1.2 APOB Gene 
Only one variant was found in APOB gene, namely in the exon 26: p.(Arg3527Gln). This is the 
most common mutation found in APOB, which markedly reduces the affinity for the LDLR leading to 
increasing levels of LDL-C in circulation. The screening of relatives in this family led to the 
identification of one more patient carrying this mutation. ACMG classifies this variant as pathogenic. 
  
3.1.1.3 APOE Gene 
One variant was found in the exon 4 of APOE gene. p.(Arg163Cys) is located in the middle of 
the α-helix H4, the LDLR-binding site. Therefore, is thought to impair LDLR-binding properties of the 
apoE protein. [123] This variant has been previously reported in Familial Type 3 Hyperlipoproteinemia 
patients from other populations. [123, 124]   
The distribution pattern of APOE polymorphisms was also investigated since it has been proven 
that these variations affect the affinity to lipoprotein receptors and, consequently, the clearance of dietary 
fat from the blood. Forty six index patients (77%) presented the most common genotype ε3/ε3. Ten 
patients presented the genotype ε3/ε4 (17%) and 1 the ε2/ε3 (2%). Finally, 3 have the ε4/ε4 genotype 
(5%).  
B. C. 
A. 
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Table 3.3 In silico predictions and ACMG classification for the variants found in this study 
 
Variant 
           In silico Prediction   
Gene Mutation 
Taster 
Polyphen 2    SIFT  PROVEAN PhyloP HSF FSPLICE NNSSP 
Overall In 
Silico 
ACMG  
Classification 
LDLR 
Exon 1 
c.1 A>C p.(?) 
Disease 
causing 
Benign Damaging Neutral 1.985 100 (1D) 100 (1D) 100 (1D) 
Non 
concordant 
Likely Pathogenic 
LDLR 
Exon 3 
c.261G>A p.(Trp87*) 
Disease 
causing 
NA NA NA 4.076 
100 (3A), 
100 (3D) 
100 (3A), 
100 (3D) 
100 (3A), 
100 (3D) 
Not applicable Pathogenic 
LDLR 
Exon 4 
c.551G>A p.(Cys184Tyr) 
Disease 
causing 
Probably Damaging Damaging Damaging 5.438 
100 (4A), 
63 (4D) 
100 (4A), 
100 (4D) 
100 (4A), 
100 (4D) 
Pathogenic Pathogenic 
LDLR 
Exon 4 
c.670G>A p.(Asp224Asn) 
Disease 
causing 
Probably Damaging Damaging Deleterious 5.864 
96 (4A), 
100 (4D) 
100 (4A), 
100 (4D) 
100 (4A), 
100 (4D) 
Pathogenic Pathogenic 
LDLR 
Exon 4 
c.693C>G p.(Cys231Trp) 
Disease 
causing 
Probably Damaging Damaging Deleterious 0.329 
100 (4A), 
100 (4D) 
100 (4A), 
60 (4D) 
100 (4A), 
68 (4D) 
Pathogenic Likely Pathogenic 
LDLR 
Exon 6 
c.862G>A p.(Glu288Lys) 
Disease 
causing 
Probably Damaging Damaging Deleterious 5.732 
100 (6A), 
100 (6D) 
100 (6A), 
100 (6D) 
100 (6A), 
100 (6D) 
Pathogenic Likely Pathogenic 
LDLR 
Intron 6 
c.941-2A>C p.(?) 
Disease 
causing 
NA NA NA 4.761 
63 (7A), 
100 (7D) 
0 (7A), 
100 (7D) 
0 (7A), 
100 (7D) 
Pathogenic 
(splicing) 
Pathogenic 
LDLR 
Intron 7 
1060+1G>A p.Gly314_Glu353del 
Disease 
causing 
NA NA NA 5.664 
94 (7A), 
69 (7D) 
100 (7A), 
0 (7D) 
100 (7A), 
0 (7D) 
Pathogenic 
(splicing) 
Pathogenic 
LDLR 
Exon 9 
c.1216C>T p.(Arg406Trp) 
Disease 
causing 
Probably Damaging Damaging Deleterious 2.637 
102 (9A), 
100 (9D) 
100 (9A), 
100 (9D) 
100 (9A), 
100 (9D) 
Pathogenic Likely Pathogenic 
LDLR 
Exon 9 
c.1291G>A p.(Ala431Thr) 
Disease 
causing 
Probably Damaging Damaging Deleterious 5.506 
100 (9A), 
117 (9D) 
101 (9A), 
100 (9D) 
100 (9A), 
100 (9D) 
Pathogenic Pathogenic 
LDLR 
Exon 10 
c.1374_1375del p.(Arg458Serfs*8) 
Disease 
causing 
Benign NA NA NA 
100 (10A), 
100 (10D) 
100 (10A), 
100 (10D) 
94 (10A), 
100 (10D) 
Not applicable Pathogenic 
LDLR 
Exon 10 
c.1432G>A p.(Gly478Arg) 
Disease 
causing 
Probably Damaging Damaging Deleterious 5.429 
100 (10A), 
100 (10D); 
101 (10A), 
100 (10D) 
100 (10A), 
100 (10D); 
Pathogenic VUS 
LDLR 
Exon 13 
c.1886del p.(Phe629Serfs*36) 
Disease 
causing 
Probably Damaging NA NA 2.151 
97 (13A), 
100 (13D) 
100 (13A), 
100 (13D) 
100 (13A), 
100 (13D) 
Not applicable Pathogenic 
LDLR 
Exon 13 
c.1897C>T p.(Arg633Cys) 
Disease 
causing 
Probably Damaging Damaging Deleterious 1.999 
100 (13A), 
100 (13D) 
100 (13A), 
100 (13D) 
100 (13A), 
100 (13D) 
Pathogenic Likely Pathogenic 
LDLR 
Exon 14 
c.2054C>T p.(Pro685Leu) 
Disease 
causing 
Probably Damaging Damaging Deleterious 5.719 
100 (14A), 
100 (14D) 
100 (14A), 
100 (14D) 
100 (14A), 
100 (14D) 
Pathogenic Pathogenic 
LDLR 
Exon 16 
c.2389G>A p.Ala771Valfs*17 
Disease 
causing 
Benign Tolerated Neutral 3.306 
100 (16A), 
88 (16D); 
New 150(16A) 
100 (16A), 
52 (16D) 
100 (16A), 
89 (16D) 
Non 
concordant 
VUS 
APOB 
Exon 26 
c.10580G>A p.(Arg3527Gln) 
Disease 
causing 
Probably Damaging Damaging Neutral 4.569 
100 (26A), 
100 (26D); 
100 (26A), 
100 (26D) 
100 (26A), 
100 (26D) 
Non 
concordant 
Pathogenic 
APOE 
Exon 4 
c.487C>T p.(Arg163Cys) 
Disease 
causing 
Probably Damaging Damaging Deleterious 2.238 100 (4A) 100 (4A) 100 (4A) Pathogenic VUS 
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Table 3.4 Comparison of functional studies results for the variants found in the LDLR and APOB genes with overall in silico and ACMG classification. 
 Variants 
Functional Studies  
Overall 
In silico 
ACMG 
Classification 
Assay Product Activity Result 
LDLR 
 Exon 3 
p.(Trp87*) Heterologous cells (CHO), FACS assays 
5-10% cell surface LDLR; 5-10% binding; 
10-15% uptake [53] 
Pathogenic 
Not 
applicable 
Pathogenic 
LDLR  
Exon 4  
p.(Cys184Tyr)  Heterologous cells (CHO), FACS assays 
Normal cell surface LDLR;5-10% binding 
and uptake [125] 
Pathogenic Pathogenic Pathogenic 
LDLR  
Exon 4 
p.(Asp224Asn) Hmz patients’ fibroblast, 125I-LDL assays <2% LDLR activity [48] Pathogenic Pathogenic Pathogenic 
LDLR  
Exon 6  
p.(Glu288Lys) 
Htz patients’ lymphocytes, FACS assays / 
Heterologous cells (CHO), FACS assays 
Normal cell surface LDLR, 40-50% LDL 
binding and uptake / Normal cell surface 
LDLR, <10% binding and uptake [53/125] 
Pathogenic Pathogenic Likely Pathogenic 
LDLR 
 Intron 7 
p.Gly314_Glu353del Htz patients' lymphocytes, RNA assays Skipping of exon 7 [74] Pathogenic Pathogenic Pathogenic 
LDLR  
Exon 9 
p.(Arg406Trp) 
Heterologous cells (CHO), FACS and WB 
assays 
60-65% LDLR cell surface, binding and 
internalization; reduced mature protein [54] 
Pathogenic Pathogenic Likely Pathogenic 
LDLR 
 Exon 9 
p.(Ala431Thr) 
Hmz patients’ fibroblast, 125I-LDL assays / 
COS7 cells 
 5-15% LDLR activity / 20% activity  
[101, 103]  
Pathogenic Pathogenic Pathogenic 
LDLR  
Exon 10 
p.(Gly478Arg) 
Comp htz patients’ fibroblast, 125I-LDL 
assays 
2-5% LDLR activity [48] Pathogenic Pathogenic VUS 
LDLR  
Exon 14 
p.(Pro685Leu) 
Hmz patients’ fibroblast, 125I-LDL assays / 
125I-LDL and RNA assays 
15-30% /20-25% LDLR activity [112/96] Photogenic Photogenic Pathogenic 
LDLR 
 Exon 16 
p.Ala771Valfs*17 Htz patients' lymphocytes, RNA assays Skipping of exon 16 [107] Pathogenic 
Non 
concordant 
VUS 
APOB 
Ex26 
p.(Arg3527Gln) 
Htz patients’ LDL, U937 cells proliferation /  
Lymphocytes, HepG2 and U937 cells / 
50 % cells proliferation / 40-50% binding and 
uptake and reduced LDL diameter [120/122] 
Pathogenic 
Non 
concordant 
Pathogenic 
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3.1.2 MLPA Analysis 
 The assessment of large rearrangements by Multiplex Ligation-dependent Probe Amplification 
(MLPA) was also performed and data analysis revealed no alterations in the group of patients under 
study. 
 
3.1.3 In silico Predictions, Functional Evidence and ACMG Classification 
The results obtained by different software packages are presented in Table 3.3.  
In silico predictions and functional studies results were concordant for 8 of the 11 variants with 
functional studies. They were not concordant for the variant c.2389G>A, p.Ala771Valfs*17 in LDLR 
with only Mutation Taster predicting its pathogenicity and for the variant c.10580G<A, p.(Arg3527Gln) 
in APOB since PROVEAN predicted the variant to be neutral. In silico predictions by Polyphen 2, SIFT 
and PROVEAN were not applicable for the intronic variants and the nonsense mutation c.261G>A, 
p.(Trp87*). SIFT and PROVEAN predictions were not applicable for the other two nonsense mutations. 
 Effects on splicing were also predicted for all variants. All missense variants were predicted to 
not affect splicing by these tools. Putative splicing variants were predicted to present alterations in donor 
or acceptor sites. In silico overall for splicing was also not concordant for the splicing mutation 
c.2389G>A, p.Ala771Valfs*17.  
Nine variants (50%) presented high PhyloP values (>+4.4) revealing their rich evolutionary 
conservation which suggests that the aminoacids codified by these conserved nucleotides must play an 
important role in protein structure and function. Eight variants presented low PhyloP scores, associated 
with poorly preserved amino acids. For c.1374_1375del variant, PhyloP score could not be calculated, 
since is a deletion of two nucleotides. 
All the variants were classified following ACMG recommendations. Ten of the 18 alterations 
were classified as pathogenic (56%). Five were classified as likely pathogenic (28%) and the remaining 
3 as VUS (17%). Not all ACMG classifications were concordant with the functional studies results: only 
7 were correctly classified as pathogenic (64%). Of the remaining, 2 were classified as likely pathogenic 
and 2 as VUS. 
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4 DISCUSSION 
4.1 Molecular Diagnosis 
Although the clinical criteria correctly identified 38% (23) of the 60 patients with familial 
hypercholesterolaemia, 62% fulfilled the Simon Broome criteria and didn’t had a mutation in LDLR 
and/or APOB. Since PCSK9 mutations are very rare, it is most likely that these patients do not have FH. 
These results prove the importance of the genetic study since the lipid profile is insufficient to predict 
who has FH.  
In the paediatric group, 12 of 25 index patients (48%) had a possible pathogenic variant in one of 
the three studied genes.  Of these 12 children, serum of 1 children was not available and, consequently, 
apoB and apoAI could not be characterized. The remaining 11 have an apoB/apoA1 ratio ≥0,68, 
correctly differentiating monogenic from polygenic dyslipidaemia in these children. In children, 
environmental factors as lifestyle, diet and exercise do not have the same influence as in adults where, 
apart from the poor diet and lack of exercise, tobacco and alcohol consumption may also interfere with 
the expression of the phenotype. For this reason, a relationship between lipid profile and the presence 
of a genetic defect is clearer, resulting in a higher genetic detection rate. In 2 of these 12 children the 
clinical criteria of FH could not be confirmed since no functional studies exist to prove the pathogenicity 
of the variants present in these patients. However, ACMG classification predicts both to be likely 
pathogenic.  
In the adults group, a putative pathogenic variant was found in 12 of 35 index patients (34%). 
Only in 9 of these adults, a proven pathogenic variant was found. Two of the remaining 3 have an ACMG 
classification of likely pathogenic and pathogenic so the variants found are most probably the cause of 
the disease. The other variant was found in APOE and ACMG classifies it as VUS.  
Cascade screening in these families allowed the identification of another 17 definite FH patients 
(4 children and 13 adults) and 2 possible FH patients. Cascade screening proved to be, this way, an 
efficient method and more cost-effective for the identification of FH patients, having identified 
approximately the same number of index cases yet, at a much lower cost. 
  
4.1.2 Mutation Analysis: Identification of Variants in the LDLR Gene 
Several possible LDLR functional mutations were found in 22 of the 60 index patients studied. 
From the 16 different possible mutations found, 10 are missense (1 with unknown effect and 9 causing 
an aminoacid change), 3 nonsense resulting in a premature stop codon and 3 putative splicing alterations. 
Patients with these variants were all found to be heterozygous. All variants will be discussed separately 
bellow. 
4.1.2.1 Missense Mutations  
c.1A>C, p.(?) exon 1 
This alteration, in the signal sequence, was observed in the first nucleotide of the exon 1 
corresponding to the initiation codon which could result in the absence of translation. This variant was 
found in one index patient and the hypercholesterolaemic mother, and has been described in other 
populations in patients with FH phenotype. [84-86] This variant is classified as likely pathogenic 
following the recommendations of ACMG. Previous studies showed that an alteration in the same 
aminoacid position but for a different nucleotide change (c.1A>T; p.Met1Leu) produces no detectable 
protein. [126] Nonetheless, only functional studies can confirm its pathogenicity meaning that the 
existing information is not sufficient to confirm the clinical diagnosis of FH. 
 
  
23 
 
c.551G>A, p.(Cys184Tyr), exon 4 
This variant was found in only one index patient (age 21) without family history of CHD. The 
aminoacid change occurs in the ligand-binding domain and has been described in other populations in 
patients with FH phenotype. [74, 87-90] Functional studies performed in heterologous cells revealed 
that the protein presents a normal expression at the cell surface and 5-10% binding and uptake. [125] 
The low rate of binding and uptake of LDL confirms that the LDLR pathway is strongly affected and 
so, the clinical diagnosis in the index patient is confirmed. ACMG classification also classified this 
variant as pathogenic. The early detection of this variant in this patient can prevent the development of 
premature CHD. 
 
 c.670G>A, p.(Asp224Asn), exon 4 
This variant was found in four apparently unrelated index patients and another four relatives were 
identified, being the most common variant found in this study. In Portugal, it is also one of the most 
common variants found. [74] Two of these four families showed a strong phenotype, with premature 
CHD in at least one family member. Several young FH patients were identified and premature CHD can 
be prevented if they start adequate therapeutic measures. The aminoacid change occurs in the domain 
responsible for the binding to apoB in LDL particles. This variant has been described in other patients 
with FH phenotype from other populations. [48] Functional studies showed that this variant in 
homozygous patients’ fibroblasts produced a protein with less than 2% of its normal activity being 
considered, this way, a null allele and so, one of the most severe mutations causing FH. [48] There is no 
doubt that this variant is the cause of the disease. ACMG algorithm classifies this variant as pathogenic. 
 
c.693C>G, p.(Cys231Trp), exon 4  
This variant was identified in only one index patient (age 45) with very high cholesterol levels 
and no CHD. This variant was already described, in other populations, in patients with FH phenotype. 
[93-95] Although ACMG classification suggests the pathogenicity of this variant, no functional studies 
exist to support it. The severity of the phenotype presented by this patient and the importance of the 
domain affected, leads to the presumption that this mutation is the cause of the disease. However, 
functional studies should be performed to confirm the clinical diagnosis of FH. 
 
c.862G>A, p.(Glu288Lys), exon 6 
This variant was found in two siblings of young age (9 and 14 years old). It was already found 
in patients with clinical diagnosis of FH in other countries. [92, 96] Functional studies performed in 
heterologous cells proved that the altered protein has normal cell surface expression and <10% of 
binding and uptake, confirming its pathogenicity. [125] This way, the variant found confirms the clinical 
diagnosis of FH. ACMG classifies this variant as likely pathogenic mainly due to the insufficient 
information about co-segregation. 
 
c.1216C>T, p.(Arg406Trp), exon 9 
This variant was found in two index patients of unrelated families, and another two relatives. 
One of these families shows a strong phenotype (values of CT above 300mg/dL) with premature CHD 
and presence of xanthelasma in one family member. Again, several young FH patients were identified 
(15 and 23 years old) and development of premature cardiovascular disease can be prevented if they 
start adequate therapeutic measures. This variant has been described in other populations in patients 
with FH phenotype. [99,100] Functional studies in heterologous cells showed that the protein expression 
in the cell surface is reduced to 60-65% as well as the binding and internalization, proving the 
pathogenicity of this variant. [54] This way, clinical diagnosis of FH in these patients is confirmed by 
the presence of this variant. ACMG classifies this variant as likely pathogenic, which can be explained 
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by the co-segregation information since not all affected patients carries the mutation. However, it has 
been shown that patients with this alteration have a very variable phenotype. [56] 
 
c.1291G>A, p.(Ala431Thr), exon 9  
This variant was found in two index patients of two unrelated families and another relative was 
identified. One of these index patients showed a strong phenotype (427mg/dL of TC and 342mg/dL of 
LDL-C, without medication) and her family presented premature CHD in more than one family member 
and presence of xanthomas. This variant was already described in patients with clinical FH in other 
populations. [90, 95, 100-104] Functional assays performed in homozygous patients’ fibroblast proved 
that the altered protein has a reduced activity of 5-15%. [101] More recently, transient expression in 
COS-7 cells revealed a reduction of the protein activity to 20%. [103] This way, the variant found 
confirms the clinical diagnosis of FH. ACMG classification also classifies this variant as pathogenic. 
 
c.1432G>A, p.(Gly478Arg), exon 10 
This variant was identified in one patient (age 64) with severe phenotype (457 mg/dL of TC and 
376 mg/dL of LDL-C without medication). Other patients with FH phenotype in different populations 
present this alteration. [48, 90, 106-108] Functional studies performed in compound heterozygous (with 
p.(Asp342Glu)) patients’ fibroblasts showed that the altered protein has 2-5% of activity in 
heterozygous, consistent with the aggressive phenotype of this patient. [48] Overall in silico predicts its 
pathogenicity but ACMG classifies this variant as VUS. This might be explained by the fact that 
functional studies in compound heterozygous are not considered in ACMG guidelines as supportive of 
a damaging effect on the gene or gene product, since the effect analysed might be a result of both 
alterations. For this reason, it is very important that this variant is assessed by functional studies, 
preferably by expression studies in heterologous cells. 
 
c.1897C>T, p.(Arg633Cys), exon 13  
This variant was found in one patient (age 16) and one relative. This variant was already reported 
in patients with FH phenotype from other countries. [109-111] Nevertheless, this is the first time that 
this variant is described in a Portuguese patient. ACMG classification suggest its pathogenicity. 
However, with no functional studies performed, the clinical diagnosis of FH cannot be confirmed for 
these patients. 
 
c.2054C>T, p.(Pro685Leu), exon 14 
This variant was found in only one patient (age 65) with a severe phenotype (280mg/dL of TC 
and 220 mg/dL of LDL-C on medication) and premature CHD (at 65 years old). FH phenotype in 
patients from other populations was already associated with this variant. [74, 107, 112-115] Functional 
studies performed in homozygous patients’ fibroblasts showed that the altered protein has 15-30% of its 
activity, consistent with the aggressive phenotype of this patient. [112] This way, the variant found 
confirms the clinical diagnosis of FH. ACMG also classifies this variant as pathogenic. 
 
4.1.2.2  Nonsense Mutations 
Three nonsense mutations were found, resulting in a premature stop codon.  
c.261G>A, p.(Trp87*) exon 3  
This variant was found in one family. The index patient is a child (age 10) with very high levels 
of total cholesterol and LDL-C (394mg/dL and 332mg/dL, respectively). The cascade screening led to 
the identification of two relatives: the sister and the mother who already had a myocardial infraction at 
the age of 34. This severe phenotype can be explained by the presence of a truncated peptide due to a 
stop codon. Functional assays performed in heterologous cells showed that the expression of LDLR in 
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the cell surface is reduced to 5-10%, confirming its pathogenicity. The binding of the altered protein to 
the LDL particle is 5-10% and the uptake is 10-15%. [53] Furthermore, this variant was already 
described in other populations in patients with FH phenotype. [86] Due to the severity of the effect 
produced by this variant in the LDLR, the finding of this variant confirms the clinical diagnosis in the 
patients studied. Following ACMG recommendations, this variant is classified as pathogenic. 
 
c.1374_1375del, p.(Arg458Serfs*8), exon 10 
This variant was found in one index patient (age 42) and her two children with 23 and 10 years 
old. The deletion of two nucleotides (AG) results in a frameshift and in the creation of a premature 
codon stop at aminoacid 466. This variant was already described in patients with FH phenotype from 
other populations [105], but no functional studies were performed to prove its pathogenicity. However, 
due to the severity of the defect (premature protein termination), the clinical diagnosis was considered 
to be confirmed. ACMG also classifies this variant as pathogenic 
 
c.1886del, p.(Phe629Ser fs*36), exon 13 
This variant was found in one child (age 8) with severe phenotype (364mg/dL of TC and 284 
mg/dL of LDL-C). Only the mother sample was available for study though the dyslipidaemia seemed to 
be inherited from the father. The deletion of one nucleotide (T) creates a stop codon at aminoacid 665. 
The clinical diagnosis was considered to be confirmed since the resultant protein is truncated. ACMG 
also classifies this variant as pathogenic.   
 
4.1.2.3 Splicing Mutations  
Most introns start with the sequence GT and end with the sequence AG (in the 5' to 3' direction). 
They are referred to as the splice donor and splice acceptor site, respectively. These two sites, together 
with the branch site, located 20 - 50 bases upstream of the acceptor site, enables the splicing of introns. 
Mutations affecting splicing are known to be pathogenic since alteration in splicing patterns of 
one or multiple transcripts will disrupt the production or function of the encoded proteins. However, 
only the determination of the differential expression of both transcripts (normal and mutant) can lead to 
a better characterization of cellular defect and help to explain the difference in phenotype observed 
between carriers of different splicing mutations. Additionally, it can lead to the identification of new 
drug targets and a more precise medicine. 
Three variants that might affect splicing were detected in heterozygous patients during this study. 
 
c.941-2A>C, p.(?), intron 6  
This variant was found in one patient (age 38) with a severe phenotype (408 mg/dL of TC and 332 
mg/dL of LDL-C without medication) and no CHD. A single base substitution of A to C at nucleotide 
941-2 causes a deletion of the acceptor site. [95] Since the splice acceptor site AG is mutated, it can be 
presumed that the splicing machinery will look for the next acceptor site, resulting in part or complete 
retention of intron 6. Nevertheless, no functional studies were performed until now and so, the clinical 
diagnosis of FH cannot be confirmed. ACMG classifies this variant as pathogenic.  
 
c.1060+1G>A, p.Gly314_Glu353del, intron 7 
This mutation was identified in two index patients of unrelated families and another relative was 
also identified. One of the index patients had a myocardial infarction at the age of 20. A single base 
substitution of G to A at the 5’ end of intron 7 causes a deletion of the donor site GT and, consequently, 
the skipping of exon 7 generating a complete different protein from exon 6 forward. The protein 
produced has a deletion of 40 aminoacids in the EGF precursor homology domain and a premature stop 
codon is generated at aminoacid 779. Functional studies were performed with heterozygous patient’s 
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lymphocytes and RNA assays. [74] This variant was firstly described in the Portuguese population. [98] 
This way, the variant found confirms the clinical diagnosis of FH. ACMG also classifies it as pathogenic. 
 
c.2389G>A, p.Ala771Valfs*17, exon 16 
This variant was found in one child (age 8) and 3 relatives. More than one family member developed 
premature CHD (ages 50 and 54). The single base substitution of G to A at nucleotide 2389, the last 
nucleotide of exon 16, creates a new acceptor site leading to skipping of exon 16 as observed during this 
study. The same result was achieved with previous functional studies performed in heterozygous 
patients’ lymphocytes and RNA studies. [107] However, only Human Splicing Finder predicted this 
new acceptor site with a splice site score of 150% when compared to the 100% of the normal acceptor 
site. On the other hand, FSPLICE predicted a considerable reduction (<88%) of the donor site splice site 
scores from 100% to 52% for the variant site.  
This mutation is likely to affect insertion of the peptide into the membrane and helix formation, 
thereby inhibiting anchoring of LDLR in the cell membrane. [55] Thus, the presence of this variant 
confirms the diagnosis of FH. Nevertheless, ACMG classifies this variant as VUS. This mutation occurs 
in the last aminoacid of the exon and ACMG guidelines only considers as strong evidence of 
pathogenicity the splice sites in the intron. For this reason, functional studies should probably be more 
considered in ACMG guidelines so that a more complete and correct classification can be achieved. On 
the other hand, in silico overall is not concordant. Three of four software packages predicted this variant 
to be benign, tolerated or neutral. This can be explained by the fact that missense variants might affect 
gene function through different ways: effect on the structure, folding or stability of the protein product. 
[57] And, as presented here, they might also cause an effect on splicing. Consequently, the possible 
disease-association of missense variants is difficult to predict, as we can observe for this case. 
 
 
4.1.3 Mutation Analysis: Identification of Variants in the APOB Gene 
Presently, more than 1700 LDLR gene mutations cause approximately 85%-90% of FH cases 
(http://www.ucl.ac.uk/ldlr/LOVDv.1.1.0/). However, mutations in APOB are thought to be responsible 
for FH in 5%-10% of cases in Northern European populations. [127] During this project, one variant 
was found in the exon 26 of APOB gene. One index patient and one relative were identified with 
c.10580G>A, p.(Arg3527Gln), the most common mutation found in APOB.  
Assays with heterozygous patients’ LDL and U937 cells showed only 50% of proliferation. 
[120] Since these cells do not synthesize cholesterol, requiring it in the extra cellular medium to be able 
to proliferate, this mutation is probably causing impairment in binding between apoB and LDLR. More 
recently, functional assays performed in lymphocytes and HepG2 cells, demonstrate that the binding 
and uptake of LDL is reduced to 50%, confirmed by proliferation assays with U937 cells. LDL size 
analysis by dynamic light scattering revealed a reduction in diameter of the LDL particle carrying the 
mutated apoB comparing to the diameter of LDL particle carrying wild type apoB, causing implications 
in binding affinity of apoB to the receptors. [122] The reduced affinity for apoB results in increased 
levels of circulating LDL-C. However, these patients have less severe LDL-C elevations compared to 
patients with LDLR gene defects, probably due to the alternative pathway for LDL clearance through 
apoE present in IDL cell surface that it is also a ligand for LDLR. [127] 
Overall in silico prediction is non concordant for this alteration. However, it has been shown that 
these methods are poor predictors of functional variations in APOB. [128] Functional studies results 
prove its pathogenicity and ACMG also classifies it as pathogenic, so the clinical diagnosis of FH can 
be confirmed for these patients.  
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4.1.4 Mutation Analysis: Identification of Variants in the APOE Gene 
4.1.4.1 APOE Mutations  
IDL and VLDL return to the liver, being cleared by virtue of apoE that serves as the ligand for 
the LDL receptor. One variant was found in the exon 4 of APOE gene: c.487C>T, p.(Arg163Cys). This 
variant is located in the middle of the α-helix H4, the LDLR-binding site. Therefore, is thought to alter 
LDLR-binding properties of the apoE protein [124], causing an impairment in IDL and VLDL 
catabolism. This variant has been previously reported in Familial Type III Hyperlipoproteinemia 
patients from other populations. [124, 123] This rare combined hyperlipidaemia is characterized by high 
levels of cholesterol and triglycerides and a high risk of premature atherosclerosis and cardiovascular 
disease and can be clinical mistaken with FH. The index patient (age 58) identified with this variant was 
also previously diagnosed with hypertrophic cardiomyopathy (HCM), which causes thickening of the 
ventricle walls. However, the severe phenotype of this patient (416 mg/dL of TC and 336 mg/dL of 
LDL-C on statins) suggests that another genetic defect might be causing the aggressive dyslipidaemia. 
Concerning to family history of CHD, her father and sister died at the age of 50 and 43, respectively, 
with myocardial infarction. 
4.1.4.2 APOE Genotyping  
APOE polymorphisms also affect the variability of plasma lipid levels, accounting for 4% to 
8% of the total variance in LDL-C levels observed in populations. [129] For that reason, it is considered 
to be an important factor in determining the development of atherosclerosis. E2, E3 and E4 are common 
protein isoforms encoded by three different alleles, ε2, ε3, and ε4. [43, 44] Carriers of the ε2 allele are 
less efficient in transferring VLDLs and chylomicrons from the blood plasma to the liver because of its 
binding properties. [42] This allele is associated with type III Hyperlipoproteinemia in homozygotes, 
which might explain the clinical diagnosis in patients with dyslipidaemia but without a mutation causing 
FH. [123, 45] None of the index patients studied was homozygous for this allele but 2% presented the 
genotype ε2/ε3. By contrast, carriers of the ε3 and ε4 alleles are more efficient in this process. Forty six 
index patients (77%) presented the most common genotype ε3/ε3. Ten patients presented the genotype 
ε3/ε4 (17%) and 3 the ε4/ε4 (5%). 
 
4.2 Patients Without Mutation  
After sequencing the whole coding region, the splice junctions and the promoter region of the 
LDLR gene, part of exons 26 and 29 of APOB and exon 4 of APOE, it was not possible to find a mutation 
in 13 individuals in the paediatric group and 23 individuals in the adults group. 
 
4.2.1 Paediatric Group 
In the paediatric group, from the 13 without a mutation only 2 had family history of CHD. 
This can be explained by the young age of their parents and even their grandparents. Nevertheless, in 
one of these families the father died from myocardial infarction (MI) at the age of 48 and in the other, 
the grandparent died at 58 years old, also from MI.  
In this paediatric group 3 had total cholesterol above 300mg/dL without medication and 3 were 
under medication with total cholesterol levels below 260mg/dL. Even so, a causative mutation was not 
found. Although it is possible that these patients have a mutation in PCSK9 or in other regions of APOB 
that were not studied, most likely their dyslipidaemia is of environmental cause. In fact, environmental 
factors as poor diet and lack of exercising can play an important role, as a high fat diet together with 
low physical exercising can increase plasma cholesterol levels in these children. If both children and 
parents have the same poor life style this would pass the false idea of an inheritance of the phenotype, 
since their parents will also have dyslipidaemia. However, the possibility of these children having a 
genetic defect in another gene involved in lipid metabolism or in cholesterol homeostasis should not be 
discarded.  
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Even if these children do not have FH they present a severe dyslipidaemia and should be 
followed and counselled so that their cholesterol levels are controlled, preventing serious implications 
as development of premature CVD. 
 
4.2.2 Adults Group 
In the adults group without a mutation, 11 had already had CHD (48%) and 12 have family 
history of CHD (52%). Total cholesterol levels above 300mg/dL are present in 9 individuals (39%) 
and 17 adults are under medication (74%). These results were not expected since all these patients 
had exactly the described phenotype of an FH patient. Severe phenotype with CHD at ages between 
42 and 61 was observed in half of this group. One patient, medicated with statins, had actually a total 
cholesterol of 339 mg/dL, being resistant to medication. However, none of these individuals 
presented tendon xanthomas. No clinical distinction between these patients and those with a mutation 
in one of the three studied genes can be observed. This suggests that other factors, not only 
environmental but genetic defects in other genes or even unstudied regions of these genes, can be 
determining the phenotype. 
 PCSK9 is involved in the regulation of LDLR, and gain-of-function mutations in this gene will 
decrease the number of LDL receptors on the cell surface resulting in LDL-C accumulation in 
circulation. For this reason, the third phase of molecular study in the Portuguese FH study is the 
screening of PCSK9 mutations in patients without a mutation in LDLR and APOB genes. The 
molecular study of PCSK9 gene should be performed for patients with aggressive phenotype, 
although only about 1-5% of FH cases are a result of PCSK9 gain-of-function mutations. [127] 
 
4.3 Diagnostic Gap 
As presented in this study, many clinically diagnosed FH patients fail to show any mutation in the 
three studied genes. The presence of mutations in other unknown and/or novel genes that are involved 
in cholesterol metabolism, may not be discarded.  Only mapping studies, as genome-wide association 
studies, to discover novel genes that might be the cause of FH will fill this diagnostic gap. Another 
possible explanation is that the genetic defect causing FH in these patients may be present in a non-
coding region of the studied genes not detected by the methodologies used in this study but that might 
affect the expression or RNA processing.  
On the other hand, FH is a disease with a great phenotypic variability. [130] These phenotypes 
result from a combination of genetic, epigenetic, metabolic, and environmental factors, different for 
every person. Corroborating with this is the observation of people carrying the same mutation with 
different lipid levels. [131, 132] Finally, some patients can also be misdiagnosed having, in fact, other 
diseases. Polygenic hypercholesterolaemia is the most common cause of elevated serum cholesterol 
concentrations, with triglyceride concentrations within the reference range. This condition is caused by 
a susceptible genotype aggravated by one or more factors, including atherogenic diet (excessive intake 
of saturated fat), obesity, and sedentary lifestyle and is associated with an increased risk for CHD. Some 
of the patients without a mutation presented high levels of cholesterol and also triglyceride 
concentrations above the reference range, clinical features of familial combined hyperlipidaemia 
(FCHL), another common polygenic disorder. 
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4.4 Final considerations 
The clinical diagnosis was confirmed for 19 of 60 index patients studied, giving a positive 
detection rate of 32%. As discussed here before, a definitive molecular diagnosis for FH is not possible 
for patients carrying variants without functional studies to prove their pathogenicity. This represents a 
serious problem for FH diagnosis and the variants identified must be functionally assessed for a definite 
diagnosis.  
The newly identified FH patients are now receiving treatment and counselling. Monitoring these 
patients is important to ensure that they follow the medication correctly and to adjust the therapeutic 
regime if needed.  This way, premature CVD, possibly leading to death, can be prevented and better 
quality of life can be achieved. Due to early detection of their disease through this study, and if treated 
correctly from early age, these children will not develop premature CHD. Thus, this study helped to 
determine the right therapeutic regime for each patient, improving patients’ prognosis. 
Nowadays, a major challenge in clinical practice is to promote medical education and awareness 
of FH to increase patients’ identification and implementing the correct treatment of these patients. 
Comparing with general population, FH patients have considerably increased CVD mortality, even if 
treated with all available lipid-lowering drugs that should be administrated during their entire lives. The 
majority of these patients remain currently undetected and increasing FH awareness in hospitals and 
general public is important to reduce their high risk for premature CHD and death. 
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Appendix I - Molecular Diagnosis of FH 
Table AI.1 Proportion of reagents per mL of blood for genomic DNA extraction 
Blood TKM X100 IGEPAL TKM1 TKM2 SDS NaCl EtOH 
1mL 1mL 25µL 1mL 160µL 10µL 60µL 460µL 
 
Table AI.2 PCR and Automated Sanger Sequencing – primers and annealing temperatures 
Exon 5’ -3’ sequence 
Amplified 
region (bp) 
Annealing 
Temperature 
Primers 
PCR 
Primer SEQ 
Promoter 
& LDLR 
Exon 1 
F:ACAAATCAAGTCGCCTGCCC 
R:GCCATTACCCCACAAGTCTCC 
MB257:GGGTTAAAAAGCCGATGTCA 
480 59º 
SPr+1F 
SPr+1R 
MB257 
LDLR 
Exon 2 
F:TCCCATACCCCAGAGAGTCCATA 
R:CAGCCGCCATCATCAAAAAG 
587 58º 
R2F 
R2R 
R2F 
LDLR 
Exon 3 
F:GGTTTCACTATATTGGCCAGG 
R:CTCCCCAGGACTCAGATAGG 
327 59º 
LDL 3F1 
MB260 
LDL 3F1 
LDLR 
Exon 4 
F:GTACAGATGAGGAAACTGAG 
R:TTGGCATGTTGTTGGAAATCC 
R4F:GAGGAAACTGAGGCACCGAG 
677 57º 
EX4F 
EX4R 
R4F 
LDLR 
Exon 5 
F:GCAAAAGGCCCTGCTTCTTT 
R:GAGGCTCTGAGAAGTCAAGT 
342 58º 
EX5F NEW 
EX5R NEW 
EX5FNEW 
LDLR 
Exon 6 
F:TGAATGAGTGCCAAGCAAAC 
R:TTCCCAAAACCCTACAGCAC 
277 59º 
MB328 
MB329 
MB328 
LDLR 
Exon 7 
F:GCGAAGGGATGGGTAGGG 
R:GCATGAGGGGTTTGGTTG 
248 58º 
MB316 
MB317 
MB316 
LDLR 
Exon 8 
F:ATCTCCCGAGAGGCTGGGCTGTCT 
R:CCCGGTCAGGGGATATGAGTCTGT 
361 59º 
MB30 
MB31 
MB30 
LDLR 
Exon 9 
F:AAGGGGATGGGGAGGCACTCTTG 
R:CCTCATCTCACCTGCGGGCCA 
397 59º 
EX9+10F 
MB277 
EX9+10F 
LDLR 
Exon 10 
F:CCTTGGCCCGCAGGTGAGA 
R:GTGCTGGGATTACAGGTGCTTTGA 
403 62º 
MB34 
MB35 
MB34 
LDLR 
Exon 11 
F:GCCACATTTGGAGTTTGGGGTTC 
R:AGCAGCTTGGGCTTGTCCCAGA 
355 60º 
EX11F 
EX11R 
EX11R 
LDLR 
Exon 12 
F:GGTGCTTTTCTGCTAGGTCC 
R:TTTTCTGCGTTCATCTTGGCT 
347 59º 
EX12F 
EX12R 
EX12F 
LDLR 
Exon 13 
F:CTAGTTGTGGAGAGAGGGTGGC 
R:GCGGAGTCAGGGCAGGAACGAG 
275 60º 
EX13F 
EX13R 
EX13F 
LDLR 
Exon 14 
F:GAAACCTCCTTGTGGAAACTCT 
R:GAAAAGTATGGTTATCCCGACT 
388 58º 
EX14F 
EX14R 
EX14F 
LDLR 
Exon 15 
F:CCAAGGTCATTTGAGACTTTCGT 
R:GAGAGAAGGTCAGCAAGGGAGTG 
388 60º 
EX15F 
EX15R 
EX15R 
LDLR 
Exon 16 
F:GTCCTCTGCCTGCTCCATTTCTT 
R:ATCCTCCATCTGACCCCTTAGC 
350 60º 
EX16F 
EX16R 
EX16F 
LDLR 
Exon 17 
F:GAGCTGGGTCTCTGGTCTCG 
R:GCGCACAGAAGCATTCACCT 
500 60º 
R17F 
R17R 
R17F 
LDLR 
Exon 18 
F:GAGCGGTGGGAAGTGACTGAAT 
R:TGGTGCCATCTGCTGTTGTGTG 
580 59º 
EX18F 
EX18R 
EX18F 
ApoB  
(exon 26) 
F:GAGCAGTTGACCACAAGCTTAGCTTGGAA 
R:GGGTGGCTTTGCTTGTATGTTCTCCGT 
343 59º 
P61 
P62 
P61 
ApoB  
(exon 29) 
F:CCAAGATGAGATCAACACAATC 
R:AACTTGACTTGAGAGTTGGG 
334 59º 
MB63 
MB64 
MB63 
ApoE 
(exon4) 
F: CTCTGGCTCATCCCCATCT 
R: ACTAGGGTCCACCCCAGGAG 
938 59º 
MB326 
MB327 
MB326 
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Table AI.3 PCR mix for genomic DNA amplification for one tube. (A) For LDLR and APOB genes, buffer, Mg2+ and TAQ 
enzyme from Bioline were used. Exceptionally, for the third exon of LDLR, the mix was prepared with equal volume of buffer 
and Mg2+ from Platinum and 0.08 µL of TAQ also from Platinum. (B) For the APOE gene, the GC Rich kit was used: the PCR 
mix is divided in master mix 1 and 2. A negative control, without DNA, was present in every PCR reaction.  
 
(A)  (B) 
 
   
 
  
 
Table AI.4 PCR for cDNA analysis – primers and annealing temperatures 
Exon 5’- 3’ sequence 
Amplified 
region (bp) 
Annealing 
Temperature 
Primers 
PCR 
Primer SEQ 
Exon 5 –
Exon 9  
F: CCAGTGCTCTGATGGAAACTGC 
R: GCCGGTTGGTGAAGAAGAGGTA 
318 62º 
MB25 
MB13 
MB25 
Exon 15-
Exon 18 
F: GGGGCCACCCCTGGGCTCAC 
R: AAGGCCGGCGAGGTCTCAGGA 
381 62º 
MB20 
MB21 
MB20 
 
 
 
Table AI.5 PCR mix for cDNA amplification for one tube.  
 
Reagents  Volume 
H20 14,625 µL 
dNTPs 1.25mM 4 µL 
Buffer 10x  2,5 µL 
Mg2+  0,75 µL 
Primer Fw (10pmol/µL) 1 µL 
Primer Rv (10pmol/µL) 1 µL 
TAQ 0,125 µL 
 Total 24 µL 
DNA (100-200 ng) 1 µL 
Reagents for Master Mix 1 Volume 
dNTPs Mix 100mM 2 µL 
Primer F(10pmol/µL) 1 µL 
Primer Rv (10pmol/µL) 1 µL 
S3 (Resolution Solution) 5M 2,5 µL 
S5 (PCR Grade Water) 10,5 µL 
Total 17 µL 
  
Reagents for Master Mix 2 Volume 
S2 (Reaction Buffer, 5x conc.) 5 µL 
S1 (Enzyme Mix, 2U/µL) 0,5 µL 
S5 (PCR Grade Water) 2 µL 
Total 7,5 µL 
Reagents  Volume 
H2O DEPC 14,67µL 
dNTPs 4µL 
Buffer Platinum 2,5µL 
Mg2+ Platinum 0,75µL 
Primer Fw a 10ρmol/µL 
Primer Rv a 10ρmol/µL 
 1µL 
1µL 
TAQ Platinum 0,08µL 
Total 24µL 
cDNA 1,5µL 
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Appendix II - Clinical Diagnosis 
Table A II.1 Clinical and biochemical characterization of studied index cases.  
 
Patient Age Sex 
Biochemical Values 
CV events 
 
Family 
history 
of CHD 
Family history 
of high 
cholesterol 
Medication TC 
(mg/dL) 
LDL-C 
(mg/dL) 
HDL-C 
(mg/dL) 
TG 
(mg/dL) 
Lp(a) 
(mg/dL) 
ApoA1 
(mg/dL) 
ApoB 
(mg/dL) 
ApoA1/
ApoB 
1 3 F 269 207 48 82 8,3 139,0 160,0 1,15 No No Yes No 
2 5 F 235 171 41 145 129,00 129,50 135,38 1,05 No No Yes No 
3 7 M 272 185 82 76 12,6 186,0 120,0 0,65 No No Yes Omega-3 
4 8 M 311 224 85 71 242,1 198,0 162,0 0,82 No No Yes No 
5 8 F 289 232 51 52 24,3 128,0 162,0 1,27 No Yes Yes No 
6 8 F 282 217 55 121 10,6 151,0 152,0 1,01 No No Yes Omega-3 
7 8 M 230 170 50 82 78,1 127,0 122,0 0,96 No No Yes N 
9 8 F 216 170 38 56 10,4 98,2 122,2 1,24 No Yes Yes 
Stanols + 
Phytosterol 
8 9 F 309 224 49 241 8,3 174,0 153,0 0,88 No No Yes No 
10 9 M 188 131 38 126 34,6 111,0 106,0 0,95 No No Yes No 
11 10 F 262 189 67 42 8,3 139,0 141,0 1,01 No No Yes No 
12 10 F 217 164 31 96 40,8 91,0 139,0 1,53 No Yes Yes Statins 
13 10 F 251 183 49 66 135 129,4 136,9 1,06 No No Yes Statins 
14 10 M 270 205 58 61 Serum not available No Yes Yes 
Stanols + 
Phytosterol 
15 11 M 286 187 83 78 Serum not available No No Yes 
Stanols + 
Phytosterol 
16 11 M 214 143 55 139 174,9 140,7 122,4 0,87 No No Yes Statins 
17 12 M 190 120 53 66 120,7 127,0 96,0 0,76 No Yes Yes No 
18 12 M 257 174 68 32 < 8,3 151,0 119,0 0,79 No No Yes Statins 
19 13 M 190 134 51 35 < 8,3 127,0 89,0 0,70 No No Yes Statins 
20 14 F 222 149 54 101 19,8 134,0 117,0 0,87 No No Yes No 
21 15 F 275 189 77 56 13,6 159,0 137,0 0,86 No No Yes No 
22 15 F 272 187 83 96 60,0 185,0 137,0 0,74 No No Yes Omega-3 
23 15 F 182 96 66 134 90,3 193,0 97,0 0,50 No No Yes Statins 
24 15 F 274 199 64 111 59,6 153,0 136,0 0,89 No Yes Yes Statins 
25 16 F 196 129 47 75 14,4 110,0 106,5 0,97 No No Yes No 
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Patient Age Sex 
Biochemical Values 
CV events 
 
Family 
history 
of CHD 
Family history 
of high 
cholesterol 
Medication TC 
(mg/dL) 
LDL-C 
(mg/dL) 
HDL-C 
(mg/dL) 
TG 
(mg/dL) 
Lp(a) 
(mg/dL) 
ApoA1 
(mg/dL) 
ApoB 
(mg/dL) 
ApoA1/
ApoB 
26 20 F 172 100 56 87 0,80 127,2 81,3 0,64 MI No Yes Statins 
27 21 F 286 198 61 161 < 8,3 206,0 159,0 0,77 No Yes Yes No 
28 21 M 314 226 67 88 H 157,9 146,2 0,93 No No Yes 
Stanols + 
Phytosterol 
29 23 F 265 175 59 193 21,6 195,0 145,0 0,74 No Yes Yes Statins 
30 29 M 184 123 43 114 18,7 131 93 0,71 No ? ? Statins 
31 36 M 231 155 43 159 128,9 123,0 147,0 1,20 MI, PTCA (36Y) Yes Yes Statins 
32 36 M 339 245 58 183 99,2 179,0 188,0 1,05 No ? ? Statins 
33 39 F 274 173 88 135 66,8 221,0 154,0 0,70 No ? ? Ezetimebe 
34 41 F 293 211 77 56 72,4 180,0 168,0 0,93 No No Yes No 
35 41 M 300 215 70 145 55,8 163,0 155,0 0,95 MI, PTCA, Angina ? ? No 
36 41 M 256 177 50 123 4,8 140,3 132,8 0,95 No No Yes Statins 
37 42 F 416 321 52 160 8,3 140,0 238,0 1,70 No No Yes 
Statins+ 
Ezetimibe 
38 44 M 183 108 62 98 11,4 151 85 0,6 No Yes Yes Statins 
39 45 F 438 357 55 119 65,1 141,0 250,0 1,77 Angina (45Y) No Yes LDL apheresis 
40 45 M 256 202 27 130 30,8 88,9 148,7 1,67 MI (42Y) Yes Yes Statins 
41 46 M 234 179 31 202 1,4 110,4 161,8 1,47 MI (43Y) Yes Yes Statins 
42 47 M 285 191 48 311 < 8,3 160,0 163,0 1,02 No No Yes Ezetimebe 
43 50 M 227 146 62 120 61,9 155,6 122,3 0,79 MI (45Y) Yes Yes 
Statins + 
Phytosterol 
44 51 F 257 156 57 247 252,8 168,0 157,0 0,93 
MI, PTCA (48Y), 
Angina, TIA 
No Yes 
Statins+ 
Ezetimibe + 
LDL apheresis 
45 51 M 164 71 57 177 73,2 139,2 94,5 0,68 MI (48Y) Yes Yes 
Statins+ 
Ezetimibe 
46 52 M 260 178 40 304 - - - - MI (46Y) Yes Yes Statins 
47 53 F 278 195 48 150 12,5 158,0 141,0 0,89 No Yes ? No 
48 54 F 255 173 63 82 17,4 157,0 131,0 0,83 No No Yes Statins 
49 55 F 165 92 54 127 54,9 155,0 88,0 0,57 
CVA (46Y), MI, 
PTCA (54Y) 
Yes Yes Statins 
50 56 F 271 199 61 145 84,5 163,0 139,0 0,85 No Yes Yes Statins 
51 57 M 234 146 52 169 34,3 161,0 115,0 0,71 No No Yes Statins 
52 58 F 194 112 64 104 8,3 148,0 98,0 0,66 No ? ? ? 
53 58 F 416 338 65 137 70,7 168,6 181,3 1,08 HC (40Y) Yes Yes Statins 
54 60 M 184 129 36 96 < 8,3 140,0 106,0 0,76 MI (55Y) Yes Yes Statins 
40 
 
55 60 F 276 185 79 75 103,4 204,0 148,0 0,73 No Yes ? 
Statins+ 
Ezetimibe 
56 62 M 167 103 47 126 39,2 135,6 96,3 0,71 MI (61Y) ? ? Statins 
57 63 F 228 159 49 120 18,1 139,0 154,0 1,11 Angina (61Y) Yes ? 
Statins+ 
Ezetimibe 
58 64 F 457 376 32 135 97,3 106,0 276,0 2,60 No No Yes No 
59 65 F 280 220 46 83 24,5 127,0 163,0 1,28 
Angina, CABG 
(65Y) 
No ? 
Statins+ 
Ezetimibe 
60 66 M 190 104 59 99 57,7 192,0 94,0 0,49 TIA (57Y) No Yes 
Stanols + 
Phytosterol 
         
 
  
 
 
TC, total cholesterol; LDL-C, Low-density lipoprotein cholesterol; HDL-C, High-density lipoprotein cholesterol; TG, triglyceride; Lp(a), Liproprotein (a); ApoAI, Apolipoprotein AI; ApoB, 
Apolipoprotein B; MI, Myocardial infarction; CABG, Coronary artery bypass grafting; PTCA, Percutaneous transluminal coronary angioplasty, TIA, Transient ischemic attack; CVA, 
Cerebrovascular accident; HC, Hypertrophic cardiomyopathy. Note: Biochemical values under cholesterol-lowering medication are presented for medicated patients. 
